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ABSTRACT: 
The medical indications for oxytocin augmentation in childbirth are inconsistent, the 
benefits of the intervention are often ambiguous and value-dependent, and there are significant 
risks, which are still being evaluated and elucidated. Providers tend to make the decision to 
augment labor without inquiring into patient preference. Rather providers declare their intent to 
augment with little or no discussion with patients, not even regarding risks, benefits and 
alternatives. In this thesis I argue that augmenting with oxytocin, in the absence of informed 
consent, violates norms of ethical clinical practice: seeking consent in cases of significant risk or 
ambiguous indications, avoidance of the generalization of medical expertise and bias in medical 
decisionmaking, and incorporation of patient preferences in shared decisionmaking. The 
introduction examines the goals and requirements of informed consent in general and as they 
relate to oxytocin augmentation. Chapter 1 argues that determination of medical need for 
oxytocin augmentation is complex and controversial. Chapter 2 explores a distinct hierarchy of 
stakeholders involved in the decision to augment, many of whom have self-interests that should 
be elucidated with patients when oxytocin is used. Chapter 3 argues, with particular attention to  
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recent feminist work, that informed consent for oxytocin augmentation should be a meaningful 
process that promotes patient autonomy and well-being, not just an expansion of a range of 
choices. Using this construction of informed consent as process, it may, at least, be possible to 
address all three of the violated norms of ethical clinical practice, even those concerned with 
bias, power structure, and preference. In addition to extensive research of the literature, the 
material presented here draws from the author’s observations during shadowing, experiences on 
the labor and delivery ward as a medical student, and from discussions with clinicians, nurses, 
and other medical students.  
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I. INTRODUCTION 
 
 
 
 
The use of exogenous, synthetic oxytocin (simply “oxytocin” from here onward) to augment 
uterine contractions in childbirth is a highly complex and multifaceted medical intervention that 
providers tend to regard as straightforward and as requiring little or no discussion with patients. 
In this thesis I will argue that informed consent is ethically required for oxytocin augmentation 
of labor and that it can be achieved consistently and in a way that privileges patient preference 
through re-structuring the patient-physician interaction to acknowledge differences in relative 
power and to begin to alter the existing power structure regarding oxytocin augmentation. The 
medical indications for oxytocin augmentation are inconsistent, the benefits of the intervention 
are often not clear, and there are significant risks, which are still being evaluated and elucidated. 
The decision occurs in a setting with a distinct hierarchy of stakeholders, many of whom have 
self-interests that should be elucidated with patients when oxytocin is used. The decision also 
concerns an aspect of childbirth about which patients have preferences and an intervention that 
can significantly change the experience of birth for laboring women, making it important to 
include patient preference in the decision to augment. 
Oxytocin augmentation is a frequent topic in discussions of the medicalization of 
childbirth among midwives, low intervention family practitioners and obstetricians, and patients 
actively trying to avoid intervention. In books and internet media, there are stories of doctors 
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ordering oxytocin1 with scant justification to nurses and patients and with little to no opportunity 
for either party to ask questions or to refuse, and of persistent pressure on those who initially 
manage to refuse the intervention to subsequently accept it. Upon hearing the general topic of 
oxytocin for this thesis, my medical school colleagues consistently mention that during their 
obstetrics rotations nearly every laboring patient has been on an oxytocin drip. This observation 
was confirmed through my own observations and clinical rotations in research for this thesis 
project. The most common justification for oxytocin augmentation was “We’re having this baby 
tonight!”, a phrase that reveals the presumed agency of the provider in the birth, particularly 
regarding when it occurs.  
I was very fortunate to have the opportunity to shadow and work with multiple midwives, 
OB/GYN-trained resident, attending, and private physicians, and family practice-trained 
physicians working in two small cities on the East Coast. I was also able to speak with numerous 
family practice-trained physicians and residents in multiple cities on the East and West Coasts 
about the topic. I observed OB/GYN-trained physicians and a midwife on the labor and delivery 
ward, spoke informally with numerous family practice-trained physicians on the subject of 
oxytocin augmentation, and observed all groups in prenatal visits. My observations and 
experiences provide examples of the problematic ways doctor-patient conversations can be 
conducted, and why at least some providers and institutions need to address the approach to 
oxytocin augmentation in discussions/interactions with patients and why all use of oxytocin for 
augmentation requires informed consent. 
In my own observations, attitudes among providers regarding oxytocin augmentation 
were varied across and within groups of like-trained providers. The physicians I observed 
                                                
1 Oxytocin is known more widely by its pharmaceutical name, pitocin. 
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practicing in a few cities on the East Coast, particularly those who were OB/GYN-trained but not 
exclusively so, largely assumed that oxytocin augmentation was of minimal decisionmaking 
import to their patients, was within their purview to give or not to give, and was a convenience to 
themselves and the patients receiving it by affording “control” over the pace and, therefore, 
duration of labor. In a Northwest city, in contrast, family practice-trained physicians with whom 
I spoke did not see oxytocin used much by their family practice colleagues or by OB/GYN-
trained physicians and thus thought even my interest in the subject undue. Some family practice-
trained physicians in a few Northeast cities, however, echoed my concerns and had themselves 
confronted colleagues, often OB/GYN-trained, about the exclusion of patient preference from 
the decision to augment. Indications for use were numerous and varied, and providers sometimes 
got angrily defensive when asked about their oxytocin related views and practices. 
Whether the usage pattern was ninety percent of births or zero,2 few providers thought it 
important to dedicate time for specific discussion of oxytocin as a possible birth intervention 
(unless the patient specifically requested a discussion); in general, providers, midwives and 
physicians alike, considered the intervention within their realm of decisionmaking, whether for 
or against its use.3 Only two providers with whom I spoke, both family practice-trained 
physicians, reported offering augmentation to patients as an option, at the point in labor when 
each provider thought it was indicated. In general, though, when oxytocin augmentation was 
                                                
2 These are subjective estimates of oxytocin augmentation given to me by providers with whom I 
worked. Ninety percent was an estimate from a private OB/GYN-trained physician. In these 
cases, oxytocin was used at some point during active labor, even if for a short duration of time. 
The midwives at the independent birth center, however never augmented labor with oxytocin. 
Midwives who delivered at the local hospital, however, were more willing to use oxytocin to 
augment, though not at the same level as their physician colleagues. 
3 Midwives, in general, chose not to recommend oxytocin augmentation at all and therefore 
chose not to discuss it with patients. Physicians, on the other hand would make a statement about 
starting oxytocin and then order it, with little to no input from the patient.  
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mentioned to a laboring patient, it was typically within a statement about an imminent use of 
oxytocin to hasten labor, as a deterrent of the slowing effects of epidural analgesics, or as a 
possibility later in the labor if the labor were to progress “slowly.” The topic of oxytocin 
augmentation was infrequently, if ever, framed as a question. In practice these attitudes regarding 
oxytocin augmentation result in the provision to patients of inadequate or no information 
regarding oxytocin. This creates an environment in which patients cannot give informed consent, 
and patients are denied the space and time to determine their preferences regarding oxytocin 
administration. 
 
 
 
 
A. THE ABSENCE OF INFORMED CONSENT REVEALS A 
MISUNDERSTANDING OF INFORMED CONSENT 
 
 
My first discussion with an obstetrician about oxytocin augmentation during my shadowing 
experience illustrates the need for a discussion of informed consent in the context of oxytocin 
augmentation. When I explained the project prompting my time with her, this physician insisted 
that an ethical exploration of consent and decisionmaking practices regarding oxytocin 
augmentation is not necessary. Even if it is not discussed at all in person with patients, this 
physician argued, it is listed in the informed consent document all patients sign upon admission 
to the hospital for labor, and therefore patients are “informed” about the intervention in an 
ethically satisfactory way. After finding the childbirth consent form, which did not actually 
include oxytocin augmentation, the physician said that oxytocin used to be on the form; its 
absence from the form, however, did not prompt her to consider a more thorough discussion of 
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consent or decisionmaking. Instead the obstetrician concluded that oxytocin does not have 
serious risks and therefore does not require any discussion with patients in person or on paper.  
Even if oxytocin augmentation is listed on the consent form, that does not mean that the 
patient understands when, why, and how oxytocin is used and what to expect about its effects to 
a sufficient degree that she can meaningfully participate in a decision about whether or not to use 
oxytocin, as she should be able to do through informed consent. The above physician’s practices 
and attitudes toward oxytocin augmentation, the lack of informed consent processes surrounding 
its use, and her assumption of the normalcy of her stance vividly illustrate the insight grounding 
my argument: oxytocin augmentation too often falls in the realm of the doctor’s largely unilateral 
decisionmaking. Such attitudes and informed consent practices create an environment that 
privileges certain information and excludes patient preference. These attitudes and practices also 
reinforce a physician role that generalizes technical medical expertise to determining a patient’s 
preference and assuming her values, particularly in a way that ignores the physician’s biases.4 In 
such an environment, it is difficult and perhaps impossible to give an informed consent or an 
informed refusal.  
 
 
 
 
B. INFORMED CONSENT REGARDING OXYTOCIN AUGMENTATION 
 
 
As is evident in the anecdote above, this physician, and many others I would later meet, 
misunderstood the goals and requirements of informed consent. The conception of informed 
consent as a form is simplistic and denies patient agency in the decision-making process, even 
though it might satisfy minimal institutional informed consent requirements, one of the next 
                                                
4 R. M. Veatch, “Generalization of Expertise,” The Hastings Center Studies (1973) 1:2, 29-40. 
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topics for consideration. My argument is concerned with enabling the obstetric patient to 
participate in decisionmaking with regard to the administration of oxytocin. The goals, process, 
and requirements of informed consent thus constitute an appropriate starting point for this 
analysis, as the argument shares its goal with the goals of informed consent, that is, preservation 
of patient well-being and patient autonomy. 
The goals of informed consent in clinical care are generally understood to include the 
promotion of patient welfare and respect for patient autonomy. Informed consent may be thought 
of in at least two senses: as autonomous authorization and as a norm-governed process involving 
patient and provider. One of the classic sources for a theoretical understanding of informed 
consent is Ruth Faden and Tom Beauchamp’s A History and Theory of Informed Consent.5 
Sense1 informed consent is “autonomous authorization.”6 As such, it is not just an agreement 
with a recommendation superficially explained and understood.7 “An informed consent in sense1 
is given if a patient or subject with (1) substantial understanding and (2) in substantial absence of 
control by others (3) intentionally (4) authorizes a professional” “to involve the subject in 
research or to initiate a medical plan for the patient (or both).”8 Informed consent in sense2 is 
“effective consent,” in that it satisfies institutional policies.9 “The social and legal practice of 
requiring professionals to obtain informed consent emerged in institutional contexts, where 
conformity to operative rules was and still is the sole necessary and sufficient condition of 
informed consent. Any consent is an informed consent in sense2 if it satisfies whatever operative 
                                                
5 R. R. Faden and T. L. Beauchamp, A History and Theory of Informed Consent (New York: 
Oxford University Press, 1986). 
6 Faden and Beauchamp, p. 277. 
7 Faden and Beauchamp, p. 278. 
8 Faden and Beauchamp, p. 278. 
9 Faden and Beauchamp, p. 280. 
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rules apply to the practice of informed consent.”10 The observed obstetrician’s idea of informed 
consent discussed above perhaps fulfills this sense2 definition of informed consent in a very 
minimal way,11 but does not necessarily satisfy the informed consent goals of well-being or 
autonomy. Disclosure has historically been, and remains by some definitions, a part of informed 
consent in sense2.12 For instance, the legal context considers disclosure integral to its sense of 
informed consent. In the medical context, however, disclosure is just the starting point of an 
effective and adequate discussion with a patient about a treatment plan. 
Both the institutional norms regarding informed consent and the goals of informed 
consent in sense1 are relevant to examination of current oxytocin administration practices. First, 
when patients are asked to authorize oxytocin augmentation at all, they rarely have all the 
requisite information to decide whether to authorize its use. Though some patients come with 
information from books, friends, family, or labor preparation classes, this may only constitute 
partial fulfillment of sense1 informed consent. When patients are not asked for authorization and 
their consent is presumed, or when patients are asked to make decisions without critical 
information, providers are violating the goals of sense1 of informed consent. Patients typically do 
not authorize oxytocin administration in an informed manner specifically; rather, patients may 
consent to it and other birth interventions “as deemed necessary by the managing physician.” 13 
Second, providers do not engage patients in an informed consent process involving disclosure of 
                                                
10 Faden and Beauchamp, p. 280. 
11 Though sense2 may be fulfilled in the anecdote above, depending on the institutional standards 
for informed consent, the fulfillment is minimal because of the physician’s emphasis on the form, 
as opposed to an embrace of informed consent as a norm-governed process that takes place 
across time and involves disclosure by physician and dialogue between physician and patient.  
12 Faden and Beauchamp, p. 281. 
13 This is an example based on some of the consent forms I have seen for childbirth. I am 
providing it to give a sense of the type of vague and broad statements that hospitals and 
providers make on and through these forms that patients sign. This is not a direct quote. 
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oxytocin’s potential risks, benefits, and alternatives, or attempt to ensure that patients understand 
that information and make a decision in keeping with their preferences, as would be consistent 
with many institutions’ norms for any medical intervention. This type of informed consent 
approach already occurs for other birth interventions like epidural analgesia. The way that many 
providers considered the form and/or its contents standard, “effective” informed consent 
regarding oxytocin augmentation may well mean these individuals thought that they were 
meeting their institutional standards for informed consent. The institutional sense of informed 
consent, however, can be achieved for augmentation in a way that is more enriched by sense1, 
thereby fulfilling the goals of sense1 as much as possible. 
Many recent works on informed consent concern the difficulty of truly achieving the 
ideals of informed consent, as classically defined by Faden and Beauchamp. Neil Manson and 
Onora O’Neill articulate an alternative conceptualization of informed consent that may be used 
to clarify why its requirements apply in the context of oxytocin augmentation. They emphasize 
that informed consent is a means whereby one party (the patient) waives the requirement of 
others (the physician) to forebear from acting in ways that would, in the absence of such consent, 
violate norms, standards or expectations.14 Oxytocin augmentation without informed consent 
constitutes a violation of norms and expectations of clinical practice: decisions about medical 
interventions with either significant risk to the patient or ambiguous indications should take 
patient preference into account; physicians have a responsibility to reflect on the power 
structures and external influences and pressures factoring into medical decisions; and childbirth 
is a natural process about which patients have preferences to be incorporated into decisions 
regarding care.  
                                                
14 N. C. Manson and O. O’Neill, Rethinking Informed Consent in Bioethics (Cambridge: 
Cambridge University Press, 2007), p. 75. 
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This account of informed consent as waiving the requirement to forebear from 
interference does not by itself delineate the scenarios that require informed consent. In the case 
of emergency interventions regarding childbirth, it is important to note that the requirement of 
informed consent is legally and ethically waived as it is for all emergency care. Some might 
argue that oxytocin is at least an urgent, if not emergent intervention, in which case there might 
be a weaker argument, ethically and legally, for informed consent. The absence of informed 
consent for oxytocin augmentation, as is current clinical practice, would be ethically acceptable 
if, and only if, oxytocin augmentation were to be considered an emergency intervention.  
It cannot be, however, that the administration of oxytocin in childbirth is routinely an 
emergent intervention. Though childbirth can have many unexpected, unpredictable moments, 
the common possibilities are known and certainly can be discussed during pregnancy in 
anticipation of their potential occurrence. Labor events can be emergency situations, and there 
may not be time to go through a complete discussion satisfying either sense of informed consent. 
In general,15 however, our structures of maternity care, unlike with emergency treatment, provide 
unique opportunities during prenatal care for childbirth preparation and for specific discussions 
about potential interventions in the birthing process. In the context of prenatal care eventuating 
in childbirth, it is therefore possible to achieve the goals of informed consent before the moment 
of urgent decision. Thus even some emergencies in childbirth may be “planned for” to a degree, 
and may not, then, have the same exemption from informed consent as other types of emergency 
care.  
                                                
15 Of course, some women first interact with the healthcare system when in labor for a variety of 
reasons, including lack of access to prenatal care. For these women, the best possible version of 
informed consent may be along the lines of the event model, as will be discussed in Chapter 3. 
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The current approach to decisionmaking regarding oxytocin augmentation violates three 
important norms: seeking consent in cases of significant risk or ambiguous indications, 
avoidance of the generalization of medical expertise and bias in medical decisionmaking through 
reflection on the hierarchy and resulting power dynamics involved, and incorporation of patient 
preferences in shared decisionmaking. Informed consent is required in the case of oxytocin 
augmentation to help avoid violation of at least two, and ideally all three, of these norms of 
ethical clinical practice. In the argument that follows, I will establish the relevance of these three 
norms to the case of oxytocin augmentation to show that informed consent is required for this 
medical intervention. In Chapter 1, I will dispute claims that oxytocin need is clear and that the 
intervention is safe, as the physician in the anecdote contended. Determination of medical need 
is, in reality, complex and controversial, making informed consent that much more vital for this 
intervention. In Chapter 2, I will explore the roles and interests of stakeholders that establish the 
labor and delivery suite as an environment in which informed consent is infrequently attempted 
and patient preference is often not sought regarding oxytocin augmentation. In Chapter 3, 
building from the exploration of relative power in Chapter 2, I argue, with particular attention to 
recent feminist work, that informed consent for oxytocin augmentation should be a meaningful 
process that promotes patient autonomy and well-being and incorporates patient preference, not 
just a process that provides an expanded range of choices. Using this construction of informed 
consent as process, it may, at least, be possible to address all three of the violated norms of 
ethical clinical practice, even those concerned with bias, power structure, and preference. 
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II. CHAPTER 1: LABOR PROGRESSION AND OXYTOCIN 
AUGMENTATION 
 
 
 
 
Labor augmentation with exogenous oxytocin is a medical intervention administered in a context 
of scientific ambiguity. Medical complications of oxytocin use are relatively rare, but they are 
serious, and response to the hormone is highly variable and therefore unpredictable. The use of 
exogenous oxytocin for labor augmentation, however, reinforces restrictive perceptions about 
normal labor progression. These perceptions, in turn, reinforce use of oxytocin augmentation in 
labors that are already progressing at a healthy and normal (even if not average) pace. The 
example of oxytocin highlights how vital open dialogue is for patient-physician interactions, 
particularly in circumstances, as with oxytocin augmentation, of ambiguous evidence. 
 
 
 
 
A. ENDOGENOUS AND EXOGENOUS OXYTOCIN 
 
 
Oxytocin is a hormone naturally produced in the human body, with a variety of physiological 
effects. Most notably for the purposes of this project, it is elevated in the female body at the time 
of childbirth via mechanisms that are not completely understood. It is a hormone produced in the 
pituitary, first synthesized in the 1950s.16 There are oxytocin receptors in many tissues in the 
                                                
16 M. Winkler and W. Rath, “A risk-benefit assessment of oxytocics in obstetric practice,” Drug 
Safety (Apr 1999) 20:4, 323-45; p. 338.  
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body, most critically in the muscle layer of the uterus. The strength of the effect on any tissue 
depends on the amount of hormone released, the type of receptor, and the number of receptors in 
the target tissue. The effect can differ greatly between individuals and result in extremely varied 
responses to the same amount of hormone, particularly throughout pregnancy, during which time 
sensitivity increases. The half-life of oxytocin is between two and ten minutes.17 Exogenous 
oxytocin is used at various points in pregnancy for different effects. High doses can be used at 
any point in pregnancy to abort a fetus by initiating contractions. More moderate doses are used 
for medically indicated induction of labor, augmentation of labor as part of the active 
management of labor (AML), augmentation of labor to manage dystocia, and prevention of 
postpartum hemorrhage due to uterine atonia.18 The female body continues to produce oxytocin 
after birth to direct milk letdown, and suckling reinforces this hormonal response. Low numbers 
of oxytocin receptors are also thought to be a major contributing factor to the asocial and 
repetitive behaviors in autism, as oxytocin has an as-yet unclear role in emotional trust and 
bonding.19 
For augmentation of labor, the laboring patient is given an intravenous drip of oxytocin. 
Contractions are monitored for strength and frequency, and the fetal heart rate is measured 
continuously and evaluated frequently.20 Contraindications to oxytocin administration include 
                                                
17 Winkler and Rath, p. 338. 
18 Winkler and Rath, p. 339. Definitions: dystocia is slow or difficult labor or delivery slow 
labor and includes both protraction, slowing of labor and arrest, cessation of labor, though these 
definitions are not used consistently, as will be discussed later; postpartum hemorrhage is 
more than 500cc of bleeding that occurs in the third stage of labor when the placenta is delivered, 
after the delivery of the fetus; postpartum hemorrhage can occur due to uterine atonia, which is 
lack of muscle tone in the muscles of the uterus. 
19 E. Hollander et al., “Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic 
and Asberger’s Disorders,” Neuropsychopharmacology (2003) 28, 193-198. 
20 For instance, a safety protocol designed by the Hospital Corporation of America’s Perinatal 
Safety Division, studied by Clark et al., recommends re-evaluation every 30 minutes. For the 
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“placenta or vasa previa, umbilical cord presentation, prior classical uterine incision, active 
genital herpes infection, pelvic structural deformities, or invasive cervical cancer.”21 One method 
of medical management for “slow” progression of labor that involves oxytocin administration is 
called the active management of labor, or AML, which was introduced by O’Driscoll and others 
at the National Maternity Hospital in Dublin, Ireland in the 1960s for nulliparous women.22 
According to Frigoletto et al., AML  
was introduced to shorten labor at a time when the rate of cesarean section was under 5 
percent. Active management of labor includes strict criteria for the diagnosis of labor, 
early rupture of the amniotic membranes, prompt intervention with high-dose oxytocin in 
the event of inefficient uterine action, and a commitment never to leave a woman 
unattended during labor. As the rate of cesarean section rose in most industrialized 
countries during the 1970s and 1980s, the persistently low rate of cesarean delivery at the 
National Maternity Hospital led other obstetrical services to use active management of 
labor as a means to reduce rates of cesarean section.23 
 
The Dublin group used AML with most nulliparous laboring patients.24 Various combinations of 
interventions have been called “active management of labor,” so in the United States, there is no 
one protocol that is universally understood to be “active management of labor.” Oxytocin is an 
oft-researched component of the AML regimen, but it is not required for AML nor is it only used 
in the context of strict AML adherence.25 AML can also include patient education through 
                                                                                                                                                       
detailed protocol, see S. Clark et al., “Implementation of a conservative checklist-based protocol 
for oxytocin administration: maternal and newborn outcomes,” American Journal of Obstetrics 
and Gynecology (Nov 2007) 197:5, 480.e1-e5; p. 480.e4. 
21 American College of Obstetricians and Gynecologists, “Practice Bulletin #49: Dystocia and 
Augmentation of Labor,” Obstetrics and Gynecology (Dec 2003) 102: 6, 1445-1454; p. 1446. 
22 ACOG, p. 1449; F. D. Frigoletto et al., “A Clinical Trial of Active Management of Labor,” 
New England Journal of Medicine (1995) 333:12, 745-750. 
23 Frigoletto et al., p. 745. 
24 Nulliparous patients are those who have never gone through childbirth before. Multiparous 
patients have borne children previously. 
25 ACOG, p. 1449. 
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Lamaze classes, “strict criteria for the determination of abnormal progress of labor, […] strict 
criteria for interpretation of fetal compromise, and peer review of operative deliveries.”26 
Multiple studies have compared the effectiveness of AML with “usual care” labor 
management, the definition of which is also highly variable and institution-dependent.27 Overall, 
it has been found to shorten the total length of labor to less than 12 hours, a reduction of 102 
minutes on average, even in the presence of epidural analgesics, which can slow birth.28 Across 
three studies, including Frigoletto et al., 91-98% of subjects delivered in less than 12 hours, up 
from 73-81% in the “usual care” groups.29 In the Frigoletto et al. study, oxytocin augmentation 
was used in up to 70% of cases in the AML group versus 56% in the “usual care” group.30 Over 
the three different studies, oxytocin was used for augmentation an average of 58% of the time in 
the “usual care” group and 65% of the time in the AML group.31 In these studies, it is striking 
how similar the rates of oxytocin augmentation are, suggesting that oxytocin augmentation is 
used in over half of all births with “usual care” practices.32 AML has also been found to decrease 
                                                
26 ACOG, p. 1449. 
27 ACOG; Frigoletto et al.; R. Rogers et al., “Active management of labor: does it make a 
difference?” Am J Obstet Gynecol  (1997) 177, 599–605.  
28 Rogers et al. The authors’ definition of labor onset is based on effacement (80%) and regular 
painful contractions (</=5 minutes between contractions). In terms of the effects of an epidural 
on labor progress and duration and need for augmentation, according to ACOG, “[l]ess 
controversial is the causal role epidural analgesia plays in prolonging labor by 40–90 minutes 
and in the approximate 2-fold increased need for oxytocin augmentation. These findings are 
supported by most prospective studies as well as meta-analyses. An increased risk of a second 
stage of labor longer than 2 hours in women with epidural analgesia likely contributes to the 
higher rates of operative vaginal delivery seen in most prospective studies” (ACOG, p. 1448). 
29 Frigoletto et al., Table 6, p. 749. 
30 Frigoletto et al., Table 4, p. 748. 
31 Frigoletto et al., Table 6, p. 749. 
32 On a national level, CDC data suggest lower rates between 10 and 19% from 1989 through 
2006. Possible reasons for usage significantly lower than the >50% suggested by Frigoletto et 
al.’s studies include the voluntary nature of data recording and submission to the CDC and the 
fact that only 19 states, of diverse geographical location and varied population density, submitted 
data to the CDC for review. Of note, the CDC did not collect data on oxytocin augmentation, or 
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rates of maternal fever without having a significant effect on cesarean section rates.33 There has 
been little success in the United States on this front,34 however, where 32.9% of births 
nationwide end in cesarean section, which has risen for the 13th year in a row, as of the most 
recent birth certificate data for 2009.35  
 
 
 
 
B. DEFINING AND DIAGNOSING NORMAL LABOR 
 
 
One of the most subjective aspects of oxytocin administration is determining when to initiate it 
for a patient in labor because data about the diagnosis of labor, prolonged labor, and labor arrest 
are ambiguous and sometimes conflicting. Identifying the “need” for oxytocin in low-risk 
childbirth is rarely done consistently beyond the practice patterns of individual providers. The 
determination of need for oxytocin augmentation depends upon the diagnosis of dystocia, or 
abnormal labor progress. Before examining abnormal labor criteria, I will first explore the 
definition and diagnosis of normal labor, which are themselves rather vague. According to the 
American College of Obstetricians and Gynecologists (ACOG), 
labor is the presence of uterine contractions of sufficient intensity, frequency, and 
duration to bring about demonstrable effacement and dilation of the cervix. At present, 
there is much uncertainty about the definition of the latent phase of labor, but there is 
agreement that women in labor enter the active phase when cervical dilatation is between 
                                                                                                                                                       
“stimulation of labor” until 1989. The CDC stopped reporting oxytocin augmentation in its 
annual public reports on birth statistics after 2006. For detailed annual reports, see 
http://www.cdc.gov/nchs/nvss.htm, particularly S. J. Ventura et al., “Advance Report of New 
Data From the 1989 Birth Certificate,” National Vital Statistics Reports (1992) 40:12, 1-32;     
M. J. K. Osterman, J.A. Martin , and F. Menacker, “Expanded Health Data from the New Birth 
Certificate, 2006,” National Vital Statistics Reports (2009) 58:5, 1-24; J. A. Martin et al., 
“Births: Final data for 2009,” National Vital Statistics Reports (2011) 60:1, 1-104. 
33 Frigoletto et al., p. 748. 
34 Rogers et al., p. 599. 
35 Martin et al., p. 13. 
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3 cm and 4 cm. The active phase is characterized by the most rapid changes in cervical 
dilatation as plotted against time. The active phase of labor includes both an increased 
rate of cervical dilation and, ultimately, descent of the presenting fetal part.36 
 
The above definition refers to the first stage of labor, which includes both latent and active labor. 
The second stage of labor occurs when full dilation (widening of the cervix to 10 cm) and 
effacement (shortening and thinning of the cervix) have been achieved. This is usually when the 
woman begins to feel a strong urge to push. The third stage of labor begins immediately after the 
fetus is delivered and primarily consists of delivering the placenta, which can be pushed out or 
manually extracted.37 This is a time of high risk for hemorrhage because the highly vascular 
placenta is separating from the uterine wall. One of the largest risk factors for third stage 
hemorrhage is uterine atonia (lack of uterine muscle tone resulting in reduced compression of the 
vessels, allowing excessive bleeding to occur). Third stage hemorrhage can be effectively, and 
often prophylactically, treated with an oxytocin IV bolus, which causes the uterine muscles to 
contract, thereby stopping the bleeding.38   
The “normal” duration of these stages of labor and what constitutes abnormal labor are 
imprecisely understood. Zhang et al. offer the most recent installment in the effort of the last two 
decades both to address the accuracy of the labor curves developed by Friedman in the 1950s and 
1960s and to redefine normal labor patterns and duration. Zhang et al. base their research on data 
from the National Collaborative Perinatal Project, a “large, multicenter, prospective, 
                                                
36 ACOG, p. 1445. The use of both “dilatation” and “dilation” to mean widening of the cervix is 
present in the original text. “Dilatation” is the correct spelling, although “dilation” is widely 
used. I will use “dilation” for consistency, as the majority of the sources I have used employ this 
spelling. 
37 “Management of the Third Stage of Labor” in “Chapter 17: Normal Labor and Delivery.” 
Williams Obstetrics, 23rd ed., F. G. Cunningham et al., eds, Last accessed 21 Jan 2012, 
http://www.accessmedicine.com/content.aspx?aID=6023669. 
38 Williams Obstetrics, Chapter 17. The oxytocin bolus is 20 units per liter of saline if the patient 
already has an IV in place or 10 units directly into the uterine wall at the time of hemorrhage. 
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observational study conducted between 1959 and 1966.”39 The data come from a time when 
“obstetric interventions in the first stage of labor were less common […providing] a unique 
opportunity to observe what may be closest to the natural process of labor in a large population.” 
Zhang et al. redefine the clinical dilation thresholds of active labor and, in so doing, make 
steps toward clarifying abnormal labor as well. They found that even multiparous women did not 
enter active labor until 5 cm dilation, surmising that nulliparous women would enter active labor 
even later.40 This is quite different from the 3 or 4 cm threshold for active labor put forth earlier 
by Friedman and used extensively in clinical diagnosis and management, even by ACOG as 
recently as 2003.41 Zhang et al. found that it “may take more than 4 hours for nulliparas to 
progress from 4 to 5 cm” (into active labor).42  In addition, “nulliparas may start the active phase 
even later [than at 5cm] and may not necessarily have a clear active phase characterized by 
precipitous dilation.” 
According to Zhang et al., their data “suggest that a 2-hour threshold [for diagnosis of 
dystocia] may be too short before 6 cm whereas a 4-hour limit may be too long after 6 cm. Given 
that the speed of cervical dilation is not constant, a graduated threshold based on the level of 
cervical dilation may be a more appropriate approach to defining labor arrest than a ‘one-size-
                                                
39 J. Zhang et al., “Natural History of the Normal First Stage of Labor,” (April 2010) 115:4, 705-
710; p. 705. For other attempts to clarify medical understanding of labor progress, see, for 
example, L. Impey, J. Hobson, and C. O'Herlihy, “Graphic analysis of actively managed labor: 
Prospective computation of labor progress in 500 consecutive nulliparous women in spontaneous 
labor at term,” Am J Obstet Gynecol (2000) 183:2, 438-443; L. L. Albers, M. Schiff, and J. G. 
Gorwoda, “The length of active labor in normal pregnancies,” Obstetrics and Gynecology (1996) 
87, 355-9; D. B. Peisner and M. G. Rosen, “Transition from latent to active labor,” Obstet 
Gynecol (1986) 68, 448-51. 
40 Zhang et al., p. 709. 
41 E. A. Friedman, “Primigravid labor: a graphicostatistical analysis” Obstet Gynecol (1955) 6, 
567–89. 
42 Zhang et al., p. 709. 
   
 18 
fits-all’ method.”43 The authors suggest, with caution, that the data indicate a more gradual rate 
of change in cervical dilation than previously reported in the literature. They argue that the 
overall shape of the curve they generated can guide revisions of clinical timelines for labor, with 
the caveat that the current laboring patient may be different from those in the study’s cohort 
because of differences in both average weight for woman and fetus and maternal age, as well as 
higher levels of early childbirth intervention, like oxytocin and epidural analgesia administration. 
An earlier study by Zhang and colleagues found that, even with the inclusion of patients 
receiving oxytocin augmentation, the slope of the labor curve is less steep and the duration of the 
active phase longer than Friedman’s curves suggest.44   
 In another article seeking to redefine normal labor, Albers, Schiff, and Gorwoda write 
specifically about some of the reasons for wide variations in the measured duration of labor and 
the resultantly limited possibility for accuracy: 
Measurement of the length of labor is inherently imprecise for several reasons. The 
starting point cannot be identified by objective means. The cervix undergoes various 
structural alterations in late pregnancy, and women do not begin labor with identical 
cervical anatomy. Labor onset is a self-diagnosis, and women vary in their recognition of 
and response to painful contractions. As such, the duration of the latent phase is 
particularly difficult to quantify. Therefore, cervical dilatation on admission to the 
hospital is often used as the first data point. The frequency of cervical examinations to 
assess labor progress varies by care provider and institution, and no consensus exists on 
examination intervals during labor. The reliability of cervical assessments is rarely 
verified and cervical change is assumed to be continuous rather than a step function. 
Recognition of the onset of the second stage of labor is also variable for both patients and 
care providers.45 
 
                                                
43 Zhang et al., p. 710. 
44 J. Zhang, J. F. Troendle, M. K. Yancey, “Reassessing the Labor Curve in Nulliparous 
Women,” Am J Obstet Gynecol (2002) 187:4, 824-828. 
45 Albers, Schiff, and Gorwoda, p. 355. Participants in the study were non-Hispanic white, 
Hispanic, and American Indian women whom midwives delivered at the University of New 
Mexico Hospital between July 1991 and June 1994. They gave birth at term after spontaneous 
onset of labor. Active dilatation was considered to be 4 cm. 
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These authors found that among 949 total study participants, none of whom received epidural 
analgesia or oxytocin augmentation, the average duration of active phase of the first stage of 
labor for nulliparous women ranged from 7 hours to 8.3 hours by ethnic group, with upper 
normal limits of up to 21.8 hours; for multiparous women, the active phase ranged from 5.3 to 
6.1 hours, with an upper normal limit of 12.5 to 15.1 hours.46 These are much longer active 
phases than the 2.5 hour average that Friedman reported in 1955 for 500 nulliparous women in 
his study, but similar to the 5.5 hours reported by Zhang, Troendle and Yancey in 2002 for 1162 
nulliparous women, about half of whom received epidurals and/or oxytocin augmentation. One 
of the strongest recommendations from Albers, Schiff, and Gorwoda and from Zhang, Troendle 
and Yancey logically follows from their findings: if normal labor durations are this variable, and 
on average this long, then new and better data and analyses are needed to establish more realistic 
diagnostic criteria for labor protraction and arrest. 47 The current understanding of labor 
protraction and arrest are explored next.  
 
 
 
 
C. DEFINITION AND DIAGNOSIS OF ABNORMAL LABOR: A CRITICAL 
READING OF THE LITERATURE ON DYSTOCIA  
 
 
Dystocia (slow or difficult labor or delivery) can result from a number of different mechanisms, 
and dystocic disorders are generally classified as protraction (slow progress) and arrest (no 
progress) disorders.48 Williams Obstetrics, a reference text in obstetrics, and the ACOG 
                                                
46 Albers, Schiff and Gorwoda, p. 357, Table 2. 
47 Albers, Schiff, and Gorwoda, p. 359; Zhang, Troendle, and Yancey, p. 827. 
48 ACOG, p. 1446; Williams Obstetrics, “Chapter 20: Abnormal Labor,” subsection “Overview 
of Dystocia,” Table 20-1. 
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guidelines use different types of criteria for diagnosing dystocia and outline different indications 
for oxytocin augmentation and cesarean section, to the point of conflict in their definitions and in 
their recommendations. Such conflict shows that indications for oxytocin augmentation are 
controversial topics that necessitate subjective decisions for medical providers. 
 
 
1.Definition and diagnosis of protraction and related indications for oxytocin augmentation 
 
 
According to Williams Obstetrics, protraction is “simply” slow labor and is measured by cervical 
dilation of less than 1.2 cm/hr for nulliparous women and 1.5cm/hr for multiparous women 
and/or fetal descent of less than 1cm/hr for nulliparous women and 2 cm/hr for multiparous 
women. The authors recommend that protraction be managed expectantly and supportively 
without oxytocin augmentation.49 According to ACOG, however, protraction disorders usually 
describe labors that are “slower-than-normal” due to problems with maternal expulsive forces 
caused by nerve or muscle damage from trauma or autoimmune disease and/or insufficient 
strength and frequency of contractions.50 These descriptions of etiology are implied to apply to 
protraction, but are directly discussed under the broader term dystocia by ACOG.51 They do not 
specify a length of time that defines “slower-than-normal” or criteria for determining adequate 
strength or frequency of contractions here. They essentially choose not to attempt to develop 
diagnostic criteria for protraction, beyond “slower-than-normal.” Thus the “objective” measures 
detailed by Williams and ACOG are entirely different: Williams focuses on cervical dilation and 
fetal descent while ACOG recommends monitoring the strength and frequency of contractions. 
                                                
49 Williams Obstetrics, Chapter 20, Table 20-2. 
50 ACOG, p. 1446. 
51 ACOG, p. 1446. 
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ACOG’s guidelines lump the two issues of arrest and protraction together for 
management and state that oxytocin augmentation is warranted “when spontaneous contractions 
have failed to result in progressive cervical dilation or descent of the fetus,”52 provided an 
anatomical arrest disorder53 has been ruled out. Cervical dilation and fetal descent criteria go 
without description for the entirety of the recommendation document, so the provider is left to 
define them independently from other sources, presumably largely influenced by predominant 
practice at his/her training and/or employment institution. ACOG authors do delineate 
contraction frequency and pressure parameters for consideration of augmentation: “if the 
frequency of contractions is less than 3 contractions per 10 minutes or the intensity of 
contractions is less than 25 mm Hg above baseline or both.” 54 ACOG then provides four 
diagnostic criteria for protraction, but only if one considers the indications for oxytocin 
augmentation to be the same as diagnostic criteria for protraction. These criteria consist of 
cervical dilation, fetal descent, contraction frequency, and contraction strength. The criteria for 
the strength and frequency of contractions in their specificity could at least provide some 
consistency of diagnosis, but dilation and descent are of no help in this regard because they are 
not specified. Interestingly, ACOG uses its diagnostic criteria as thresholds for intervention with 
oxytocin augmentation, thereby leaving no situation in which protraction might be expectantly 
managed. Their specific frequency and strength criteria also suggest that ACOG considers these 
                                                
52 ACOG, p. 1446. 
53 Anatomic arrest disorders, which are managed with cesarean section, include cephalopelvic 
disproportion, where the fetal head is larger than the pelvic passageway through which it must 
travel, and problems of fetal position such as breech. Skilled and experienced providers 
sometimes attempt vaginal delivery for breech position (depending on the perceived fetal 
orientation in each individual, unique case) in hospital and insurance settings that permit such 
attempts. In many places, however, breech positioning is considered a contraindication to vaginal 
birth. 
54 ACOG, p. 1446. 
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stronger indications for oxytocin augmentation than the vague dilation and descent indications. 
ACOG implies that once a labor is deemed “slower-than-normal” intervention is warranted, and 
ACOG gives a fair degree of subjective control to the provider over whether or not to augment. 
Williams, on the other hand, is more specific with “objective” parameters for diagnosis of 
protraction, but recommends expectant management, implicitly acknowledging the wide range of 
“normal” labor rates and durations, encouraging much more conservative use of oxytocin for 
augmentation when specifically discussing protraction than currently occurs in practice.  
Indications for oxytocin augmentation span scenarios considered to be both protraction 
and arrest in Williams as well as in ACOG. According to Williams’ authors the indications 
include prolonged latent phase, defined as lasting more than 20 hours and arrest disorders 
including prolonged deceleration phase, secondary arrest of dilation, or arrest of descent.55 
However the description of augmentation indications by the Williams’ authors could well pertain 
to protraction as well as arrest: “if contractions are not adequate—less than 200 Montevideo 
units56—and if the fetal status is reassuring and labor has arrested, an oxytocin infusion dose 
greater than 48 mU/min has no apparent risks.”57 By focusing on risk, or, rather, their 
interpretation of its absence, Williams’ authors avoid discussion of any other factors that might 
                                                
55 Williams Obstetrics, Chapter 20, Table 20-2. 
56 This is a measure of contraction pressure and a threshold typically considered to indicate 
inadequate contractions. The import of such pressure parameters have been challenged by Rouse 
et al., who found that this threshold was not predictive of delivery method in oxytocin 
augmented births: of nulliparas, 83% of women who never achieved 200 M. units delivered 
vaginally after a minimum of 4 hours of oxytocin augmentation for labor arrest compared to 75% 
of women who inconsistently achieved 200 M. units delivering vaginally and 85% of women 
who consistently achieved greater than 200 M. units; of multiparas, 97% of women who never 
achieved 200 M. units delivered vaginally, compared to 94% of women who inconsistently 
achieved 200 M. units delivering vaginally and 94% of women who consistently achieved 
greater than 200 M. units (D. J. Rouse et al., “Active Phase Labor Arrest: Revisiting the 2-Hour 
Minimum,” Obstet Gynecol [October 2001] 98:4, 550-554, p. 553, Tables 2 and 3). 
57 Williams Obstetrics, “Chapter 22: Labor Induction,” subsection “Labor Induction and 
Augmentation With Oxytocin,” subsection “Maximal Dosage,” emphasis added. 
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go into the decision to augment, such as patient preference or other subjective factors. As should 
be evident, ACOG and Williams measure and handle these abnormal labors differently, and it is 
quite difficult to compare management strategies when the Williams authors and ACOG use 
different terminology and different diagnostic criteria. What is clear, however, is that this lack of 
consistency sets the stage for a lack of clinical consensus regarding the indications for oxytocin 
augmentation. This environment of scientific uncertainty or inconsistency, in turn, makes the 
role of patient preferences and the need for informed consent all the more acute. 
 
 
2. Definition and diagnosis of arrest and related indications for oxytocin augmentation 
 
 
Oxytocin augmentation for arrest disorders specifically is muddled, since arrest and protraction 
can be defined in overlapping ways. The lack of clarity in Williams and ACOG derives from 
using the single word “arrest” when discussing different problems at different stages of labor. A 
graduated, or step-wise, approach for diagnosis and treatment of arrest is implicit in these 
sources but not fully explained. Arrest disorders are diagnosed when “complete cessation of 
progress” has occurred, according to ACOG.58 A few etiologies of arrest disorders are actually 
contraindications to oxytocin augmentation, including the anatomic etiologies of arrest 
mentioned earlier like cephalopelvic disproportion or breech fetal position. These are largely 
known before labor onset, yet make it that much more important to correctly determine the cause 
of an arrest disorder before intervening.59 Oxytocin is generally only used for first stage arrest 
(before pushing begins), which should only be diagnosed after 4 cm dilation or once active labor 
has begun. According to Williams, the most common criterion for diagnosis of first stage labor 
                                                
58 ACOG, p. 1446. 
59 ACOG, p. 1446. 
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arrest is a lack of progress for more than two hours, though it is unclear in Williams whether this 
time limit is a threshold for putting patients on an oxytocin drip or a threshold for resorting to 
cesarean section, for the nature of the “intervention” is not specified.60 
ACOG, on the other hand, uses the criteria delineated earlier for indications to augment 
in the management of arrest, but also admits that a more expectant protocol for arrest 
management by Rouse, Owen and Hauth “appears effective.”61 In this protocol, Rouse, Owen, 
and Hauth encourage more expectant management after starting oxytocin and before diagnosing 
full labor arrest and resorting to a cesarean section by recommending at least 4 hours of oxytocin 
augmentation. In their study group, they found that up to 6 hours for women whose contractions 
were below the 200 Montevido unit level was safe.62 Most (92%) of their study group achieved a 
vaginal birth.63 This 8% cesarean section rate would have been 26% if they had gone to cesarean 
section after seeing no progress with 2 hours of oxytocin augmentation. It is worth noting that 
93% of their study group had epidural analgesia before oxytocin augmentation was started.64 
Based on these findings, ACOG reports that 4 to 6 hours, as outlined above, appear to be 
acceptable new minimums of oxytocin augmentation duration, depending on a patient’s strength 
of contractions. 
                                                
60 Williams Obstetrics, “Chapter 22. Labor Induction.” Section “Labor Induction and 
Augmentation with Oxytocin,” subsection “Duration of Oxytocin Administration,” subsection 
“Active Phase Arrest.” Typical understanding and practice of the 2-hour minimum is explained 
by Rouse, Owen, and Hauth as follows: usually two hours with little to no cervical change (1 cm 
or less in 2 hours) justifies oxytocin augmentation, and no progress two hours after the start of 
oxytocin has been the threshold for a diagnosis of full arrest, for which cesarean section is 
indicated (D. J. Rouse, J. Owen, and J. C. Hauth, “Active-Phase Labor Arrest: Oxytocin 
Augmentation for at Least 4 Hours,” Obstetrics and Gynecology [March 1999] 93:3, 323-328;   
p. 324). 
61 ACOG, p. 1447. 
62 Rouse, Owen, and Hauth p. 326. 
63 Rouse, Owen, and Hauth, p. 327. 
64 Rouse, Owen, and Hauth, p. 327. 
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Much of the work discussed here is a start toward redefining normal and abnormal labor, 
but there is still much work to be done and decisions to be made in the meantime as to how to 
manage normal birth and how to determine what is abnormal. The conflicting and confusing 
state of the recommendations right now means that it is largely up to individual providers and 
their local colleagues such as fellow members of a practice or hospital department to decide how 
and when to use oxytocin augmentation. 
 In practice, exogenous oxytocin is widely used for labor that is “slow to progress,” 
without a strict diagnosis of dystocia, protraction, or arrest because guidelines are inconsistent, as 
discussed above. Data about the point in labor at which oxytocin is administered have not been 
broadly or uniformly collected, except from those institutions and states submitting data on 
oxytocin augmentation to the CDC between 1989 and 2006. In acknowledgment of this, the 
Institute for Healthcare Improvement, an “independent not-for-profit organization helping to lead 
the improvement of health care throughout the world […] by building the will for change, 
cultivating promising concepts for improving patient care, and helping health care systems put 
those ideas into action” recently led an initiative to get more specific data about oxytocin 
augmentation.65 Their chart review form for obstetrical providers, which was publicly available 
on their website in 2010, included five recommended documentation components to encourage 
and assess clinical practice of safety measures regarding oxytocin administration: estimated fetal 
weight prior to oxytocin administration, normal fetal status before and during oxytocin 
administration (two components), written indication of a complete pelvic examination, and 
evidence of evaluation for, recognition of, and management of tachsystole of uterine contractions 
                                                
65Institute for Healthcare Improvement, “About IHI,” (2011) Last accessed 21 January 2012, 
http://www.ihi.org/about/pages/default.aspx. 
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(more than 5 contractions in 10 minutes averaged over 30 minutes).66 It is important that 
hospitals and providers choose to record their data so that usage patterns can be broadly 
evaluated. 
 
 
 
 
D. THE DANGERS OF LONG LABOR 
 
 
As I have shown, diagnosis and management of “slow” or abnormal labor progress is vague at 
best. Implicit in interventions that shorten labor is the belief that long labor is dangerous. Long 
labors have been associated with particular negative outcomes, which shortening labors could 
theoretically help to avoid. Albers, Schiff, and Gorwoda looked for associations between 
prolonged labor and four different labor complications that have been associated with long 
labors: “postpartum hemorrhage, defined as estimated blood loss of greater than 500 mL after 
delivery; postpartum fever, defined as an oral temperature of greater than 100.4 F within 24 
hours of delivery; infant resuscitation, defined as assisted ventilation with bag and mask or 
endotracheal intubation; and a 5-minute Apgar score less than 7.”67 In their assessment, patients 
did not receive epidural analgesia or oxytocin. They did not find a greater association between 
these complications and prolonged labor compared to non-prolonged labor.68 Aside from Albers, 
                                                
66 Institute for Healthcare Improvement, “Augmentation Bundle Data Collection Tool,” (2010) 
Last accessed 20 June 2010, 
http://www.ihi.org/about/pages/default.aspx>http://www.ihi.org/IHI/Topics/PerinatalCare/Perina
talCareGeneral/EmergingContent/AugmentationBundleDataCollectionTool.htm. Data collection 
for this project closed in August 2010 and the website was no longer accessible when checked on 
January 21, 2012. 
67 p. 356. The Apgar score is a subjective scale of neonatal well-being that involves the 
assessment of muscle tone, color, breathing, heart rate, and reflexes. 
68 Albers, Schiff, and Gorwoda, p. 357. Their definition of prolonged labor is as follows: greater 
than 19.4 hours for the active phase in nulliparous women and 12.7 hours for the active phase in 
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Schiff, and Gorwoda, research on this subject is limited, and further investigation is warranted. 
Based on the findings of this study, however, long labor may not be as risky as the frequent 
evaluations of labor progress and the prevalence of intervention to hasten labor might suggest. 
The findings do not suggest that long labor is benign, either; rather, the authors encourage 
patience and more expectant, watchful management of labor than is typical practice currently as 
the medical community continues to learn more about normal and abnormal birth. 
 
 
 
 
E. OXYTOCIN: BENEFITS AND RISKS 
 
 
 The risks and benefits of oxytocin and their significance are debated in the literature. 
Oxytocin has well-established benefits through administration at specific junctures in labor. For 
instance, it is widely used in the third stage of labor to reduce bleeding as the placenta is 
delivered. This provides significant protection against uterine atonia, which can lead to life-
threatening post-partum hemorrhage.69 To prevent or limit postpartum hemorrhage, a large bolus 
dose is administered to the patient right after delivery of the baby (called the third stage of labor), 
which has been shown to greatly reduce maternal blood loss.70  
There are undeniable time-related benefits of oxytocin augmentation for patient and 
provider.71 Many people who are in any type of pain would welcome an offer to shorten the 
duration of that pain through medication when possible. As found by Frigoletto et al., oxytocin 
                                                                                                                                                       
multiparous women; greater than 147 minutes for the second stage in nulliparous women and 57 
minutes for the second stage in multiparous women. 
69 Winkler and Rath, p. 324 and 339. 
70 Winkler and Rath, p. 339. 
71 S. L. Clark et al., “Oxytocin: new perspectives on an old drug,” Am J Obstet Gynecol (2009) 
200, 35.e1-e6; p. 35e3. 
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administration keeps 91-98% of labors studied under 12 hours.72 There are certainly some direct 
benefits to the laboring patients in shortening labor such as avoiding exhaustion and shortening 
the length of suffering. Moreover, providers may feel like they have more control with oxytocin 
because labor is more predictable. I explore the implications of this perception of control in 
Chapter 2. 
Despite these advantages, the medical administration of oxytocin has some severe side 
effects, some of which can be extremely dangerous to both mother and infant. One of the more 
common side effects of oxytocin administration is increased pain and discomfort due to greater 
strength and frequency of contractions and, therefore, increased pressure, which was the major 
finding of a 2009 meta-analysis of 9 different clinical trials of oxytocin augmentation.73 Wei et 
al. chose studies which compared patient outcome after early oxytocin administration for 
slowness of a spontaneous, low-risk labor to progress or as part of AML to the outcomes of 
groups more conservatively managed (slower to use oxytocin); the criteria for “slowness” varied 
significantly between studies.74 The authors sought to “estimate the effects of early oxytocin 
augmentation for delay in labor on method of delivery and on indicators of maternal and 
neonatal morbidity.”75 They found that early oxytocin had some benefit: it increased the number 
of vaginally completed births by 1 per 20, decreased the need for antibiotics during and after 
labor (need defined by presence of fever), and slightly reduced (though not enough to be 
statistically significant) both the cesarean section rate and the operative delivery rate. However, 
early oxytocin increased the risk of uterine hyperstimulation and was associated with lower 
                                                
72 Frigoletto et al., p. 749, Table 6. 
73 S. Q. Wei et al., “The Effect of Early Oxytocin Augmentation in Labor: A Meta-Analysis,” 
Obstet Gynecol (Sept 2009) 114: 3, 641-649 ; p. 641. 
74 Wei et al., p. 643. 
75 Wei et al., p. 642. 
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patient satisfaction with pain management because of increased pain and discomfort.76 Wei et al. 
conclude by recommending a discussion with patients about oxytocin’s benefits and the potential 
for increased pain and discomfort.77 This recommendation assumes that there is an existing 
framework for discussions with patients about oxytocin augmentation, but as I will discuss more 
in Chapters 2 and 3, this is not an accurate assumption in the case of oxytocin augmentation in 
many practice environments.  
Uterine hyperstimulation is a widely agreed-upon, serious, but rare side effect of oxytocin 
use. Excessive oxytocin administration, which depends on each patient’s unique dose response, 
can lead to hyperstimulation and morbidity.78 Like many other drugs used in pregnancy, some of 
the most serious health risks and unknowns are for the fetus rather than for the mother, 
reminding us of the complex relationships in pregnancy between providers, fetuses, and the 
pregnant woman. This is the case with morbidity related to uterine hyperstimulation. Fetal 
morbidity due to hypoxia and acidemia (both of which compromise fetal oxygenation) is a 
serious potential side effect of hyperstimulation of the uterus.79 A large Swedish study (28,486 
deliveries) not only links prolonged hyperstimulation of the uterus to fetal morbidity, but also 
suggests direct negative effects on the fetus due to oxytocin by an as-yet unknown mechanism.80 
                                                
76 Wei et al., p. 646-7. 
77 Wei et al., p. 647. This meta-analysis did not use studies with enough power to detect serious 
maternal or fetal side effects. 
78 Clark et al. (2009), p. 35.e2. 
79 M. Jonsson et al., “Acidemia at birth, related to obstetric characteristics and to oxytocin use, 
during the last two hours of labor,” Acta Obstetricia et Gynecologica Scandinavica (2008) 87:7, 
745-50; p. 749. 
80 Jonsson, p. 749. 
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Oxytocin exposure from induction or augmentation has also recently been associated with an 
increased likelihood of attention deficit hyperactivity disorder for the infant later in life.81 
For the laboring patient, risks of adverse outcomes specifically due to oxytocin have been 
largely dismissed in the literature due to rarity. Established, though rare, risks for the mother 
include hypernatremia and hemorrhage. At high doses (>20U/min infusion), oxytocin can cause 
hypernatremia, or excessive retention of sodium, due to mimicry of another natural hormone in 
the body.82 While this effect is dose dependent it is also more likely when the drug is rapidly 
infused with large volumes of normal saline.83 This effect is extremely dangerous for the patient 
and can lead to “confusion, cramps, coma, heart failure.”84 Even though oxytocin is a powerful 
and widely used treatment for post-partum hemorrhage (PPH), a recent study suggests that large 
doses and prolonged duration of oxytocin exposure during labor actually increases the risk of 
serious PPH, defined as the patient requiring a blood transfusion, secondary to uterine atony.85 
On average, among the 54 PPH patients and the 54 controls, PPH patients had received 
significantly larger total doses of oxytocin, more than double the duration of exposure, and their 
maximum oxytocin doses were more than double those of the control group.86 The authors 
suggest that the uterine atony observed is likely related to oxytocin receptor desensitization due 
to prolonged exposure to oxytocin.87 
                                                
81 L. Kurth and R. Haussmann, “Perinatal Pitocin as an Early ADHD Biomarker: 
Neurodevelopmental Risk?” Journal of Attention Disorders (2011) 15:5, 423-431. 
82 Winkler and Rath, p. 340. 
83 Winkler and Rath, p. 340. 
84 Winkler and Rath, p. 340. 
85 C. A. Grotegut et al., “Oxytocin exposure during labor among women with postpartum 
hemorrhage secondary to uterine atony,” Am J Obstet Gynecol (Jan 2011) 204, 56.e1-e6. 
86 Grotegut, p. 56.e4. 
87 Grotegut, p. 56.e5. 
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As discussed above, many of the risks associated with oxytocin infusion are dose 
dependent and therefore theoretically largely preventable. Thus many of the problems that arise 
are due to medication error. According to a 2008 study on medication errors, 4.8% of voluntarily 
submitted medication errors over a three-year period involved obstetric care.88  Of these obstetric 
medication errors, 48% occurred during labor and delivery89 and over 70% of these labor and 
delivery errors occurred during medication administration.90 Reporters named oxytocin 
specifically in 22% of all reports of harm-causing medication errors in obstetric care.91 
According to another study, oxytocin infusion errors most often involved a lack of appropriate 
treatment of excessive doses of oxytocin as evidenced by unacceptably high frequency of 
contractions and/or fetal distress per fetal heart rate patterns, accidental infusion of oxytocin with 
normal saline, and inappropriately early use of oxytocin for induction of labor.92  
There are also risks inherent to any medication dependent upon the way it is delivered. 
Intravenous infusion of medication has well known potential complications that all nurses are 
trained to recognize that include local or systemic infection, infiltration (delivery of the infusion 
into soft tissue instead of into the blood stream, often because the catheter in the vessel has 
become dislodged), and phlebitis (inflammation of a vein due to chemical/mechanical irritation 
of the vascular tissue). 
The ambiguities enumerated here with regard to oxytocin’s indications and benefits as 
well as the largely preventable, though serious and sometimes fatal, risks have led to two 
                                                
88 T. A. Kfuri et al., “Medication Errors in Obstetrics,” Clinics in Perinatology (2008) 35, 101-
117; p. 108. 
89 Kfuri et al., p. 108. 
90 Kfuri et al., p. 109. 
91 Kfuri et al., p. 113. 
92 K. R. Simpson and G. E. Knox, “Oxytocin as a high-alert medication: implications for 
perinatal patient safety,” American Journal of Maternal/Child Nursing (Jan-Feb 2009) 34:1, 8-
15; p. 8-9. 
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initiatives in the last five years: a safety warning and an initiative to make dosaging and 
monitoring more uniform. The Institute for Safe Medication Practices is a federally certified, 
non-profit patient safety organization that functions through donations. The Institute recently 
brought some negative attention to oxytocin by putting it on their high-alert list of medications. 
The medications and drug classes on the list can cause serious injury if used incorrectly, more so 
than drugs that are not high alert.93 As of 2007, there were eighteen classes of medications 
considered high alert, and twelve medications specifically discussed, IV oxytocin among them. 
The Institute bases its recommendations on survey results from medical providers across the 
country.94 Seven hundred seventy health care providers, primarily nurses and pharmacists, 
answered the survey in 2007. A substantial majority of the nurses, those actually administering 
the drugs, indicated that oxytocin should be considered a high-alert medication while 
pharmacists, who are more removed from the drug’s application, expressed less concern: 73% of 
nurses surveyed voted to put oxytocin on the list versus 38% of pharmacists.95 
As a result of ambiguous efficacy and safety findings regarding oxytocin, much attention 
has been brought over the last few years to the need for uniform dosing.96 According to these 
studies, the lack of standardization of oxytocin dosaging poses the largest risk to patients, due to 
                                                
93 Simpson and Knox, p. 8. 
94 For more information see: Institute for Safe Medication Practices, “About ISMP,” (2012) Last 
accessed on 21 Jan 2012, http://www.ismp.org/about/default.asp. 
95 Institute for Safe Medication Practices, “ISMP 2007 survey on HIGH-ALERT medications: 
Differences between nursing and pharmacy perspectives still prevalent,” (May 17, 2007) Last 
accessed 21 Jan 2012, http://www.ismp.org/newsletters/acutecare/articles/20070517.asp. 
96 Clark et al. (2009); Clark et al. (2007); E. J. Hayes and L. Weinstein, “Improving patient 
safety and uniformity of care by a standardized regimen for the use of oxytocin,” Am J Obstet 
Gynecol (June 2008) 198:6, 622.e1-e7; Jonsson et al.; L. R. Mahlmeister, “Best practices in 
perinatal care: evidence-based management of oxytocin induction and augmentation of labor,” 
Journal of Perinatal and Neonatal Nursing (Oct-Dec 2008) 22:4, 259-63; L. A. Miller, 
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its dose-dependent side effects. However, as previously mentioned, a “standard” dose may not be 
an achievable goal due to individual variations in physiological response to oxytocin, so the 
focus has been mainly on the formation of protocols for incremental, lowest need dose oxytocin 
administration with close monitoring of maternal and fetal indicators of morbidity.97 An article 
from 2008 called for much more cautious use of oxytocin augmentation, not just in terms of 
dosage, but concerning overall usage. The authors, Romano and Lothian argue, as I have hinted 
in this chapter, that oxytocin augmentation is a symptom of a larger issue in our healthcare 
system of overlooking ambiguity of evidence and privileging existing high-intervention practices 
without questioning them, under the assumption that technology and synthetic hormones are safe 
and beneficial entities with minimal risk/harm. 98  
In this chapter, I have discussed the medical and scientific communities’ evolving and 
continuing efforts to more fully understand childbirth and the resulting ambiguous nature of the 
indications for an oxytocin augmentation for “slow” labor. The benefits of hastening labor and 
therefore decreasing duration of labor are largely subjective both for providers and for patients 
due to its impact on the experience of labor, leaving a great deal of room in decisionmaking for 
preference distinct from medical “need.” While it is often assumed to be “safe” by providers 
utilizing it, as the physician in the anecdote assumed, this is not accurate for either fetal or 
laboring patients due to the direct effects of the synthetic hormone and risks of medication error, 
in particular.  
As I will explore in Chapter 2, oxytocin augmentation is a decision made almost solely 
by providers. Authors like Romano and Lothian note that oxytocin augmentation is often used 
                                                
97 For an example of a recent protocol initiative see Clark et al. (2007) and Clark et al. (2009). 
98 A. M. Romano and J. A. Lothian, “Promoting, Protecting, and Supporting Normal Birth: A 
Look at the Evidence,” Journal of Obstetric, Gynecologic, and Neonatal Nursing (2008) 37, 94-
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because of “arbitrary time restrictions,” both personal and professional, influencing provider 
decisionmaking.99 Professional pressures, personal timing considerations and other factors that 
impact decisionmaking will be the focus of Chapter 2.  There, I will evaluate the interactions that 
occur between providers and patients and the influences on the major parties involved, setting 
the stage for an exploration in Chapter 3 of possible approaches to informed consent regarding 
oxytocin augmentation that take into account the biases and generalization of expertise identified 
in Chapter 2. 
                                                
99 Romano and Lothian, p.99. 
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III. CHAPTER 2: DECISIONMAKING AND PATIENT-PROVIDER 
INTERACTION 
 
 
 
 
In Chapter 1, I established that oxytocin is an intervention with highly subjective 
indications dependent upon inconsistent, ambiguous, and, in one instance, meaningless 
diagnostic criteria for normal and abnormal labor. In this second chapter, I will discuss the 
interests of, and influences on, the major stakeholders involved in the decision to augment with 
oxytocin, with particular attention to the relationships and pressures of relative power. My 
analysis is informed by my observation of, and participation in, patient care as a medical student. 
Giving birth tonight instead of tomorrow is advantageous for many stakeholders, providers and 
patients alike, and is an advantage that can be hard to balance against other considerations within 
an environment of hierarchical power.  
 
 
 
 
A. A LOOK AT THE STAKEHOLDERS, INFORMED, WHERE 
APPLICABLE, BY DIRECT OBSERVATIONS 
 
 
Providers, including physicians, midwives, and nurses, pregnant women and their fetuses are all 
stakeholders involved in childbirth and oxytocin augmentation.100 All share an interest in health 
and safety for laboring patients and their fetuses, but each party brings a framework for decisions 
                                                
100 Hospitals and payers as representatives of system-based influences were explored, but little 
data was available so they will not be discussed in this work. 
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made and actions undertaken during labor and delivery. Each individual involved brings his or 
her own training, experiences, professional pressures, and personal interests that form his or her 
practices and preferences. Any of them may have personal values and fears regarding the 
intervention based on their own or their significant other’s laboring experience, if they have had 
children, which might also affect his/her professional choices. Larger entities like hospitals and 
payers bring previous experience and self-interest, including financial interests, to bear on their 
policies. A few small studies even suggest that a combination of such subjective factors, 
particularly those influencing physicians, may be playing a role in higher rates of intervention 
and more numerous operative delivery outcomes, independent of individual patient factors.101 
One study’s authors observed higher rates of caesarean section, oxytocin use, and epidural use 
among women randomly assigned to be admitted to the hospital during the latent phase of labor, 
compared to women sent home during latent labor who returned and were admitted for active 
labor.102  
 Providers are under complex pressures and influences when deciding whether or not to 
augment labor with oxytocin. As established in the introduction, providers often assume that the 
decision is theirs to make and do not include patients in the decision-making process. I argue that 
informed consent is ethically required for oxytocin augmentation of labor and that it can be 
achieved consistently and in a way that privileges patient preference through re-structuring the 
patient-provider interaction to acknowledge difference in relative power and to begin to alter the 
existing power dynamics regarding oxytocin augmentation. There is one part of the decision to 
augment, however, that the provider makes alone: specifically, the determination of medical 
                                                
101 L. J. Bailit et al., “Outcomes of Women Presenting in Active Versus Latent Phase of 
Spontaneous Labor,” Obstetrics and Gynecology (Jan 2005) 105:1, 77-79; p. 79. 
102 P. S. McNiven et al., “An early labor assessment program: a randomized, controlled trial,” 
Birth (1998) 25, 5-10. 
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need for oxytocin augmentation informed by training and expertise. If a patient has a 
contraindication to oxytocin augmentation, for instance, oxytocin augmentation would not be 
appropriate and would not be offered. Thus whether or not the intervention is even an option is 
the provider’s decision. Ideally, the provider would then seek informed consent to interventions 
from among the options available, and the patient could express her preferences. In my 
observation, however, the typical physician extends his/her power over the entire decision-
making process regarding oxytocin augmentation, not just the determination of medically 
appropriate options. It is important to note that providers, particularly physicians and midwives, 
also control how and when to convey those options to patients. Admittedly, however, the timing 
of a patient’s presentation to the clinic for prenatal care or the hospital for labor can also very 
much impact the degree to which each patient can realistically be involved in a decision. For 
instance, a provider can choose to talk about augmentation during prenatal care, upon admission 
to labor and delivery, or right before ordering the hormone for administration. 
 Provider control of decisionmaking power constitutes a generalization of expertise, 
conceptualized by Robert Veatch as occurring “when, consciously or unconsciously, it is 
assumed that an individual with scientific expertise in a particular area also has expertise in the 
value judgments […] simply because he has scientific expertise.”103 According to Veatch, 
generalization of medical expertise to judgments involving values is never appropriate because 
training in the one area does not instill knowledge or expertise in the other, and because the 
values involved are frequently personal ones for those impacted by the decision. The practice of 
providers deciding about oxytocin augmentation for patients, involves the assumption that the 
provider knows what patients would want for themselves, specifically what treatment plan 
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fulfills their vision of a good or acceptable childbirth or promotes their well-being. This 
constitutes an example of generalization of expertise. In addition to being subject to 
imperfections in understanding of patient perspectives, moreover, providers’ medical expertise is 
not independent of external and internal factors such as their own localized cultures and their 
personal practice experiences. These factors may very inappropriately fill the gap in provider 
understanding of patient perspectives, values, and preferences and would also be a generalization 
of expertise.  The following subsections explore factors that impact the ways that physicians 
make decisions and interact not only with patients but also with other providers. 
 
 
1. Providers: Physicians 
 
 
a. Training, experience, practice culture, and professional pressures 
 
 
Training, experience and practice culture inevitably influence physician decisions. There are a 
few specific situations in which oxytocin augmentation is contraindicated and therefore 
recommendations are straightforward. The contraindications described are rare, so relatively few 
cases that physicians manage will meet definitive criteria. The indications in the absence of 
contraindications, as discussed in Chapter 1, are ambiguous. The rate of labor progression should 
be the major factor weighed when evaluating a patient’s medical need for oxytocin. As 
mentioned in the introduction, however, personal observations and discussions with providers in 
a few different practice types and locations suggest that rate of labor is not always the main 
criterion for oxytocin augmentation. In addition, as discussed in Chapter 1, the medical and 
scientific communities imperfectly understand the progression of labor, and “slow” is a relative 
and subjective term. In this clinical setting of scientific ambiguity, an individual physician’s 
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interpretation of the evidence regarding abnormal and normal labor will certainly be affected by 
the interpretations of those with whom s/he trained and practices and her/his own personal 
experiences.   
 In my observation and informal discussions, the influence of using an epidural on the 
need for oxytocin is largely training-based, rather than evidence-based. For example, I witnessed 
some providers order nurses to start a continuous intravenous infusion of oxytocin right after the 
epidural had been started, without any confirmation that the contractions had actually changed in 
any way. Such an order suggests that these providers consider oxytocin a “necessary” 
countermeasure to an epidural, without evidence of medical need. In fact, the effects of epidurals 
on labor duration depend on when in labor the epidural is initiated, and study results are often 
inconsistent. In a systematic review comparing 7 different studies, epidural analgesia did not 
have a statistically significant effect on the duration of the first stage of labor and only slowed 
the second stage of labor by 15 minutes, on average.104  
 Experience with oxytocin augmentation, personally and professionally, is another factor 
that might influence a physician’s decision for or against augmentation. Frequency and severity 
of side effects in a physician’s previous patients may have a large impact, for instance. Number 
of labors overseen with and without augmentation may also influence a physician in either 
direction. Each provider’s practice pattern, his or her training, as well as the predominant 
practice culture at each institution are likely to affect whether or not oxytocin augmentation is 
used.  
 
                                                
104 B. L. Leighton and S. H. Halpern, “The effects of epidural analgesia on labor, maternal, and 
neonatal outcomes: A systematic review,” Am J Obstet Gynecol (May 2002) 186:5, S69-S77; p. 
S75, Table III. 
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 Based on observations and discussions, I found that patient load at any given moment 
may strongly influence a physician’s decisions about oxytocin augmentation. A scheduled 
cesarean section later in the day or the number of labors anticipated to be in the second stage at a 
given time under the supervision of the same provider may encourage a provider to augment 
labor in order to have some “control” over the timing of the labors with which s/he must assist. 
There may be pressure on a provider from his/her hospital to keep labor rooms turning over. 
Patient load and system-based distinctions between nurse and physician responsibilities are the 
major reason physicians are not in the room as much as nurses and also maybe a reason 
physicians are ordering oxytocin in ways that nurses deem “unsafe,” thereby creating conflict 
between nurse and physician. According to Simpson, James, and Knox, oxytocin is reportedly 
often cited as a source of disagreement between the labor nurse, who is present in the room for 
most of the patient’s labor, and the attending physician or resident, who is in the room only 
intermittently.105 In this study, nurses were most often resistant to starting or increasing oxytocin 
doses while physicians consistently wanted “aggressive” augmentation, with the difference of 
perspective leading to failures in communication and tension in the workplace.106 There could 
also be situations where the reverse is true, in which the nurse is pressuring the physician to use 
oxytocin and the physician is resistant. 
 
 
b. Personal interests, values, and fears 
 
 
Personal interests, values, and fears may also play a role in a physician’s decision to augment. 
For instance, if a physician trained where 90% of births were augmented, one could speculate 
                                                
105 K. R. Simpson, P. C. James, and G. E. Knox, “Nurse-physician communication during labor 
and birth: Implications for patient safety,” J Obstet Gynecol Neonatal Nurs (2006) 35, 547-50. 
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that s/he may simply be impatient with a slower-paced labor. Anxiety or fear about not having 
“control” as one does with oxytocin could be related to this impatience. For instance, one family-
practice-trained physician reported that she prefers to use oxytocin in all labors she manages 
because it is a low-risk way to keep a labor progressing, and it is easy to change the dosage if 
there is too much or too little of an effect. For this physician, oxytocin was a tool to keep things 
at a pace acceptable to her according to her personal and professional preference. Essentially, she 
used oxytocin because the use of oxytocin reassured her, the physician. She reported telling 
patients that it would keep labor on track.  
 A physician could have also mistakenly ordered oxytocin when there was a relative or 
absolute contraindication for a patient or been sued about oxytocin use in the past. These could 
easily make him/her reluctant or anxious about using it again. On the other hand, a physician 
could have had a bad outcome in the absence of oxytocin in a patient, herself, spouse, or a family 
member, been sued over not ordering oxytocin, or been reprimanded for not ordering oxytocin 
soon enough or at all. In this case, the physician might overuse oxytocin augmentation out of fear 
when put in a similar position to make a decision about augmentation. Making decisions based 
primarily on these personal factors on the part of physicians would not be in patients’ best 
interest and would constitute an inappropriate generalization of expertise. 
 
 
2. Providers: Midwives 
 
 
a. Training, experience, practice culture, and professional pressures 
 
 
In my observation, attitudes and interactions about oxytocin augmentation in the course of a 
normal labor generally differed based on the type of institution and, therefore, environment in 
   
 42 
which the providers worked and trained, particularly for midwives. Generally speaking, it is the 
case that midwives use oxytocin infrequently for augmentation. Much of the midwifery literature 
is insistently opposed to oxytocin augmentation, and the training focuses on low intervention in 
normal births. Though I did not directly observe oxytocin’s use by midwives, some of the 
midwives with whom I spoke said they had noted their own practice patterns, or those of fellow 
midwives, changing. The biggest factor seemed to be the practice environment. For example, the 
midwife I observed working out of a free-standing birth clinic stated that the clinic’s policy was 
to use oxytocin only in the third stage of labor to prevent post-partum hemorrhage. There might 
have been a rare occasion during her training elsewhere when she or another midwife might have 
used it to augment labor, but she could not recall a specific instance of this. 
 In contrast, the hospital-based midwife I observed stated that she had recognized and 
lamented her practice patterns changing to become more like those of the physicians around her 
since she had started working in a hospital. In the hospital where she worked, the midwives were 
responsible for teaching the residents in low-risk, normal deliveries, thereby empowering the 
midwifery view in this particular hospital setting. Indeed, the labors and deliveries I observed 
were quite low intervention, and oxytocin was used much less and with more conscious 
reflection on the part of providers than in the other hospital in which I spent time. The midwives 
have to have physician oversight throughout the labor, however, and a physician has to be in the 
room at the time of birth. The loss of important privileges as independent care providers for 
birthing mothers, determined by hospital policy and state law, make it extremely hard for these 
midwives to maintain the practice patterns of their initial training, despite the potential to gain 
respect and good rapport with their physician colleagues through teaching. The increased use of 
oxytocin is one aspect of the erosion of their training-inculcated practices. 
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b. Personal interests, values, and fears 
 
 
Midwives’ values likely influence their choice of profession; in this respect the choice of the low 
intervention approach of midwifery likely reflects midwives’ personal values against 
interventions like oxytocin augmentation. On the other hand, however, there may also be 
personal factors involved in changing practice patterns toward using more oxytocin for 
augmentation based on the practice environment. For instance, if midwives are practicing in a 
high intervention setting like a hospital, the patient population may have expectations that more 
intervention equals better care, particularly if the patient did not specifically choose a midwife 
for her care. This may, in turn, become a matter of personal interest for the midwife in an effort 
to build a patient base in a community that values more intervention. In addition, midwives 
might also come to use oxytocin or continue to avoid it for some of the same personal reasons as 
physicians, or out of fear of repeating prior outcomes or litigation concerns. 
 
 
3. Providers: Nurses  
 
 
Nurses and physicians have very distinct roles in today’s labor and delivery suites. Nurses are 
present in the room with one or two patients for a significant amount of the labor, whereas 
physicians are more often out of the room than in it, at least until the second stage begins. It is 
the nurses who most directly support these patients who are in pain, exhausted, and sometimes 
overwhelmed with all that is happening. Due to their extended time with patients, which is not 
necessarily unique to labor and delivery units, nurses might make management suggestions,  
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depending on their training and experience, but it is the physician who usually has the final 
decision and who must order the drug or intervention. 
 Based on my observations and informal discussions, I found that nurses can have a 
significant impact on a laboring patient’s experience, and may directly affect which interventions 
a patient “needs” or wants. At a few institutions on the West coast, for instance, family medicine 
residents and attendings alike touted that the reason for their low oxytocin augmentation and 
epidural rates is focused, supportive nursing care for each laboring patient. A systematic review 
of studies regarding pain control and patient satisfaction found that, in 16 studies, perceived 
caregiver support had a large impact on patient satisfaction.107 For instance, “[i]n one US-
Canadian study, 44% of the variance in satisfaction was explained by women’s ratings of the 
quality of intrapartum nursing support.” In a randomized controlled trial of one-on-one nursing 
support for laboring women, those patients with one-on-one support showed a small trend of 
reduced requests for epidural analgesia that was not statistically significant, and a large and 
statistically significant decrease in oxytocin requirement, compared to the usual nursing 
technique group.108 
 The power dynamics with physicians regarding oxytocin augmentation in other places, 
however, seem to be particularly inflexible,109 and nurses may have to work in a system that 
denies them the agency to advocate for their laboring patients regarding oxytocin augmentation. 
During my labor and delivery rotation at an East Coast/Midwest institution, for example, I 
                                                
107 E. D. Hodnett., “Pain and women’s satisfaction with the experience of childbirth: A 
systematic review,” Am J Obstet Gynecol (May 2002) 186:5, S160-S172; p. S167. 
108 A. J. Gagnon, K. Waghorn, and C. Covell, “A randomized trial of one to one nurse support of 
women in labor,” Birth (1997) 24, 71-77; p. 75, Table 2. 
109 The inflexibility of power structure between nurse and physician regarding initiation of 
oxytocin administration was indicated in Simpson, James, and Knox’s article about nurse and 
physician disagreements over oxytocin augmentation as mentioned in section 1. a. above. 
   
 45 
witnessed one disagreement in which a nurse refused to start an oxytocin infusion the physician 
had ordered. She was an experienced nurse who was well acquainted with the physician 
involved, which likely gave her confidence to voice her own opinion about the intervention. The 
physician had taken the nurse’s advice about other concerns regarding this particular patient, but 
on augmentation he held firm. Observations by Clark et al. (2009) echo this type of disagreement 
between nurse and physician over oxytocin augmentation:  
Our experience in assessing and improving obstetric practices in many hundreds of 
different institutions has led all the authors to 1 identical conclusion: the most common 
cause of discord between obstetrician and labor nurse is the tendency of a physician not 
at the patient’s bedside to urge the use of oxytocin in a manner deemed unsafe by the 
bedside labor nurse.110 
 
Clark et al., a group of three physicians and one nurse, go on to argue that the party with more 
experience, usually the bedside labor nurse, is often correct.111 In my experience, the ultimate 
decisionmaking power in such a disagreement typically, however, goes to the physician. 
Theoretically then, such a rigid hierarchy and inappropriate generalization of expertise by 
physicians in such cases could actually be a safety risk for patients if Clark et al. are correct in 
their conclusion that the more experienced labor nurse is usually in the right regarding oxytocin 
augmentation. 
 A nurse may have little control over whether a physician starts oxytocin once that 
physician determines “need,” but s/he does have power over the titration of the hormone after it 
has been started. Once the infusion is on, it is the nurse’s responsibility to ensure the patient’s 
safety in relation to the effects of oxytocin and the efficacy of the intervention: if a patient is not 
progressing, the nurse must increase the dose according to the protocol established by the 
hospital where s/he practices; on the other hand if a patient develops uterine hyperstimulation, 
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the nurse must either decrease or stop the oxytocin infusion, depending on her clinical judgment 
and training, before involving the physician who ordered the oxytocin.112 So while nurses may 
not control the initial use of oxytocin, they have a great deal of responsibility for and control 
over the way it is used once it is started. Thus, they are personally invested in oxytocin’s safe use 
just as much, if not more than, physicians are invested, at least in terms of personal liability.  
 
 
a. Training, experience, practice culture, and professional pressures 
 
 
The use of oxytocin for augmentation directly affects the way nurses interact with laboring 
patients. A physician must order the oxytocin, but it is the nurse who must set up the drip, and it 
is the nurse, not the physician, who must increase the frequency of patient exams and watch 
closely for fetal heart rate changes and contractions getting too close together. Thus, oxytocin 
may make just two patients challenging to manage simultaneously. Due to the hierarchy often 
present between nurses and physicians, nurses often have little recourse to contest a 
recommendation for oxytocin augmentation with which they disagree. Nurses may also be 
concerned about physicians’ limited discussion, or complete lack of discussion, with patients 
regarding oxytocin. Furthermore, the increased pain levels of oxytocin-augmented labors for 
patients, as compared to labors without oxytocin, may be seen more clearly by nurses than 
physicians, in part because nurses spend more time with patients during labor. These additional 
oxytocin-associated factors—increased patient management pressures, patients’ increased pain, 
and patients’ lack of understanding of their experience with or need for oxytocin—may increase 
tension between nurses and physicians, and may affect nurses’ interactions with their patients. 
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 Nursing training plays into how comfortable each nurse is with this supportive role of the 
laboring patient as well as comfort with oxytocin administration and monitoring. Even though 
nurses are often intentionally assigned to patients experiencing alternate stages of labor (i.e. one 
in early labor and one in late labor) when possible, labor rarely follows a predictable course. 
When it does, as might be said for oxytocin-augmented labors, the nurses are not often able to 
take advantage of the “predictability” of labor progression to check on another patient because 
oxytocin has increased the nurse’s monitoring requirements. According to one study about 
communication between nurses and physicians during labor, the majority of nurses interviewed 
were resistant to keeping a patient’s labor on a predetermined timeline, which the nurses often 
felt was the physician’s personal timeframe rather than one devised for the patient’s best 
interest.113 In this qualitative research project, a large patient burden on the unit was another 
reason cited by nurses to delay or disagree with a physician-requested initiation of, or change in, 
oxytocin management, because these nurses felt that they could not monitor these patients 
frequently enough at a busy time to keep the patient and the fetus safe.114  
 
 
b. Personal interests, values, and fears 
 
 
Nurses’ professional experiences may influence fear or favor of oxytocin augmentation, 
depending on the outcomes of patients they worked with in the past. Perhaps a previous patient 
experienced a rare or serious side effect, or the nurse him/herself made a mistake with 
administration or missed important problems in the fetal heart tracing or contraction pattern. On 
the other hand, a nurse might have witnessed numerous positive labor experiences and outcomes 
                                                
113 Simpson, James, and Knox, p. 549. 
114 Simpson, James, and Knox, p. 549. 
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with oxytocin augmentation. On the level of personal interests, a nurse, like a physician, might 
prefer oxytocin augmentation because of the shorter labor time. Alternatively, a nurse might 
have a preference against augmentation due to the increased monitoring required. A nurse may 
or may not support a decision to augment for fear of litigation as well. Acting on these interests, 
values, and fears on the part of nurses is not necessarily in the patient’s best interest, and 
awareness of them brings insight to nurses’ interactions with patients. 
 
 
4. Obstetrical Patients 
 
 
a. Considerations in the decision-making process 
 
 
Unless the patient is informed and educated about the birth process and the interventions that can 
be provided, through books, websites, articles, friends, or family, the patient derives much, if not 
all, of her information about treatment options from her provider. As I have observed, some 
patients may not have any information on which to base a decision regarding oxytocin 
augmentation because informed consent has not been attempted. 
If a laboring patient is informed, however, and is facing oxytocin augmentation or any 
intervention, she has a range of factors to consider. Her health and safety and those of her fetus 
are major concerns, though it is impossible to predict whether these concerns alone would 
support a positive or negative patient preference regarding oxytocin augmentation, because even 
the “objective” evidence on safety for patient and fetus is ambiguous. A patient may desire a low 
intervention birth, and therefore, on principle, wish to avoid oxytocin augmentation. A different 
laboring patient may want to manage and “control” her vaginal birth as much as possible and 
therefore desire oxytocin augmentation and probably an epidural as well. Physicians and other 
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providers certainly cannot definitively predict the ways in which such preferences might affect a 
patient’s ultimate decision about oxytocin augmentation, when these preferences are weighed 
among other factors. Thus it is important to involve patients in the actual decision-making 
process. 
 
 
b. Conditions influencing decisionmaking 
 
 
Pain, hunger, and exhaustion impact decisions. Fear of pain or wish to avoid pain may, quite 
understandably, drive a patient to plan an early epidural, or intense experience of pain during 
labor may lead a patient to request an epidural she wasn’t planning to have. A preference for 
oxytocin augmentation may also be related to a preference for shortening the duration of a 
patient’s pain. For a patient without an epidural, however, avoidance or fear of pain may mean a 
preference against oxytocin augmentation, given the increase in frequency and strength of 
contractions, and therefore in pain, it causes. In another patient, hunger and exhaustion may 
influence her to desire a shorter labor, and oxytocin augmentation, whatever the change in pain 
level. For patients without insurance or without full coverage of labor costs, the higher cost of 
the labor room may also be a factor influencing patients to request or accept oxytocin 
augmentation to shorten labor.  
As in the case of all the stakeholders already discussed, previous experience may also 
have a significant impact on a patient’s preference. A laboring patient may have had a previous 
birth experience in which oxytocin was used with increased pain, or serious side effects for 
herself or her fetus, and the patient may fear a repetition of the prior experience and therefore 
want to resist or refuse augmentation. There may also be an association from a prior birth 
experience between oxytocin and a bad outcome like stillbirth, in which oxytocin would be given 
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to induce labor after fetal death is confirmed so that the fetus could be delivered in the absence of 
spontaneous labor. On the other hand, a patient may have been pleased with an actively managed 
labor in the past and may wish to repeat it by accepting or even requesting oxytocin 
augmentation. 
Given all of the factors that influence the patients, providers, and nurses involved with 
oxytocin augmentation, navigating patient-provider interactions and discussions is 
unquestionably complicated, and ensuring that conditions are created to enable informed consent 
could be challenging. Interactions with patients about oxytocin augmentation may even be 
personally challenging because many of the factors, pressures, and influences mentioned here 
require serious self-reflection for both patient and provider. How then should we think about 
these interactions, what they need to achieve, and how they should be conducted? Informed by 
the exploration of bias, power, and influence in this chapter, the following chapter will suggest a 
method for re-structuring the patient-provider, particularly the patient-physician, interaction in 
ways that provide meaningful choice for patients while specifically avoiding providers’ 
generalization of expertise as now occurs in oxytocin augmentation decisions.
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IV. CHAPTER 3: INVOLVING THE OBSTETRICAL PATIENT IN 
DECISIONS REGARDING OXYTOCIN AUGMENTATION 
 
 
 
 
In this thesis, I have discussed the goals and requirements of informed consent, highlighted the 
absence of informed consent for oxytocin augmentation, and explored two of the three clinical 
norms that are violated through the absence of informed consent. Informed consent is needed for 
oxytocin augmentation due to its risks and unclear indications, as well as the many influences 
and pressures on, and unequal power dynamics amongst, the stakeholders. Informed consent is 
also necessary because of the personal experiential nature of the process of childbirth, about 
which patients have preferences and expectations. This chapter involves articulating different 
conceptions of informed consent in practice and then considers how to incorporate preferences 
through a method that empowers patients to take an active part in the decision-making process. 
In this chapter, I discuss an approach to the patient-physician interaction that empowers pregnant 
patients to participate in decisions regarding oxytocin augmentation. This method could allow 
informed consent’s goals of patient well-being and autonomy to be achieved in a way that 
privileges patient preference and encourages awareness, if not removal of, the biases that 
reinforce the current unilateral power dynamic and generalizations of expertise that hamper 
decisionmaking about oxytocin augmentation.  
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A. INFORMED CONSENT IN PRACTICE 
 
  
The need for greater patient involvement in birth decisions is highlighted by a 2002 study in 
which 40% of US patients who did not initially want an epidural received one, compared with a 
UK study which found that only 10% of patients who did not plan an epidural eventually 
received one.115 The comparison suggests that US providers and UK providers could be 
educating patients differently: prenatally, US providers may not be adequately educating patients 
about the birthing process and their options, so that patient preferences are unrealistic, or such 
education is not accessible to the same percentages of patients as in the UK; perinatally, US 
providers may be encouraging intervention more than necessary and/or patients may not be 
adequately empowered to defend their preferences. 
There are myriad factors involved in the patient-physician interaction in the context of 
medical decisionmaking that can impede or encourage the substantial understanding about a 
given medical intervention that informed consent ideally achieves and depends upon. An 
examination of the interaction will elucidate the ways in which informed consent can be 
achieved to more fully address the social, institutional, and personal factors for the individuals 
involved. Authors Jessica W. Berg, Paul S. Appelbaum, Charles W. Lidz, and Lisa S. Parker 
describe typical formats of informed consent attempts in Informed Consent: Legal Theory and 
Clinical Practice.116 Berg et al. argue that sense2 informed consent typically occurs in practice in 
two dominant ways, a “process model” and an “event model.” A “process model” of informed 
consent occurs slowly over time, often in the context of a long-term patient-physician 
                                                
115 T. R. Marmor and D. M. Krol, “Labor Pain Management in the United States: Understanding 
Patterns and the Issue of Choice,” Am J Obstet Gynecol (2002) 186:5, S173-S180; p. S176. 
116 J. W. Berg et al., Informed Consent: Legal Theory and Clinical Practice, 2nd ed. (Oxford: 
Oxford University Press, 2001). 
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relationship, and may even achieve both senses of informed consent articulated by Faden and 
Beauchamp:  
The advantages of a process model are substantial. The process model promotes the 
objectives of the underlying idea of informed consent and, at the same time, is equally in 
conformance with the requirements of the legal doctrine of informed consent as the 
event-oriented approach. Patients are brought actively into the decisionmaking process, in 
a manner that encourages their knowing participation. They receive information, over 
time, in a fashion that allows it to be contemplated, shared, and assimilated. Further, by 
participating in the stream of decisions as they are made, patients are not excluded from 
the “ultimate” decision, by virtue of being excluded from the many preliminary decisions 
that may, in effect, predetermine the outcome. 
 
[…Also, it] should serve to make the idea of informed consent meaningful to physicians. 
No longer is the disclosure and decision-making process divorced from the real decisions 
that need to be made.117 
 
Berg et al. contrast this process model of informed consent, with its emphasis on 
disclosure of information and subsequent shared decisionmaking, with an “event model.” An 
“event model” of informed consent is one in which patients are given a minimal amount of 
information to make a decision and are encouraged or expected to make a decision at the time of 
disclosure, without time to consider the information, form additional questions, or seek 
additional counsel. Berg et al. argue 
[T]he event model appears to be structured in the worst possible way as far as facilitating 
patients’ informed participation is concerned. Educators have long known that provision 
of information repetitively, over a sustained period, results in better understanding and 
better retention than exposure at a single point. Information provided when patients are at 
relative ease is more effectively assimilated than information offered at times of stress. 
The event model encourages “one-shot” education of patients, with little opportunity for 
reflection and integration of the information obtained into the patients’ underlying 
scheme of values, and at a time, given that a decision must be made imminently, when 
patients’ anxiety is likely to be at a peak.118 
 
                                                
117 Berg et al., p. 172-73. 
118 Berg et al., p. 170. 
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The “event model,” then, specifically precludes the understanding and much of the participation 
described above as being at the core of sense1 informed consent. The “event model” is heavily 
provider and institution-driven as a result. This “event model” is the most accurate description of 
informed consent in the setting of oxytocin augmentation in current practice, if any attempt at 
informed consent occurs at all. 
A great deal of a patient’s education goes on in birthing classes and prenatal visits, but 
oxytocin augmentation is rarely specifically addressed, thus the only women becoming well 
informed about it are women who have already done their own reading or are asking questions. 
Even women who take advantage of structured childbirth education time prenatally can have 
limited access to information from providers regarding oxytocin augmentation specifically. 
When they do get information it is sometimes from nurses or midwives with views regarding 
oxytocin augmentation that contradict their labor provider’s views. There are structures in place 
to pursue informed consent according to the “process model” approach taken with other 
childbirth topics during prenatal care, but it cannot be achieved unless advantage is taken of that 
structure and time. Even more widespread use of an “event model” of informed consent for 
patients who go into labor early or do not receive prenatal care would be an improvement from 
the absence of disclosure or dialogue with most patients’ augmentations. 
 Patient-physician interaction during the medical decision-making process has important 
implications for informed consent. The method discussed next seeks to empower the patient, 
provide information, satisfy informed consent requirements, and provide space in the discussion 
for clarifying and exploring the patients’ preferences. Janet Farrell Smith’s application of the 
communicative ethics model to medicine attempts to achieve these goals through acknowledging 
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and making more visible underlying power structures so that both parties’ values can be 
represented and respected.119  
 
 
 
 
B. COMMUNICATIVE ETHICS: A PARADIGM FOR INFORMED CONSENT 
INTERACTIONS BETWEEN PATIENTS AND PHYSICIANS 
 
 
Smith’s account of communicative ethics involves revising existing clinical practice and 
changing the nature of the encounter in question. Communicative ethics occurs when speakers in 
an open forum “critically analyze existing norms, explore new ones, and come to mutual 
understanding or consensus.”120 According to Smith, conceptualizing communication as just a 
transfer of information, as too often occurs in current interactions, is “too limited even to account 
for the normative importance of information in physician-patient discourse.”121 Moreover, most 
existing patient-physician interactions are not a free exchange of speech acts in a medical 
context, but a “highly structured discourse in which the physician is usually very much in 
control.”122 The information transfer approach to communication, which Manson and O’Neill 
also criticize, fails in four ways: it allows for a conflation of factual and prescriptive statements 
which can be influenced by the perceived role and status of the doctor,123 does not highlight the 
                                                
119 J. F. Smith,  “Communicative Ethics in Medicine: The Physician – Patient Relationship,” in 
Feminism & Bioethics: Beyond Reproduction, S. M. Wolf, ed. (New York: Oxford University 
Press, 1996) 184-215. 
120 Smith, p. 184. 
121 Smith, p. 185. 
122 Smith, p. 187. 
123 This observation bears significant resemblance to Veatch’s concept of the “generalization of 
expertise” discussed in Chapter 2. 
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importance of facts and information in contrast to opinion and provider preference, does not 
encourage dialogue, and does not acknowledge differential access to power.  
The patient-provider form of communication she envisions is more than the simple and 
inadequate transfer of information because it must conform to ethical principles of respect and 
moral equality, which the transfer of information does not do. Importantly, the communicative 
ethics approach both allows for disagreement to occur without a failure of the interaction and 
acknowledges “differential power and access to technical knowledge” between patient and 
physician.124In order for this to occur, the approach encourages a step back from the encounter to 
allow analysis of how speech acts guide, coordinate, and interpret action, with eventual 
consensual action being the central goal. It is unclear from Smith’s account exactly how or when 
this stepping back is to occur and who is to undertake it. By stressing that the medical encounter 
should resemble a conversation more closely than an interview, Smith implies that both parties 
must step back: the party with more power, typically the provider, must evaluate the way s/he 
presents “fact” versus opinion or recommendation and must identify where patients, without the 
same knowledge base, may require more detailed explanation of common medical assumptions, 
terms or processes. The party with less power, typically the patient, must reflect on what s/he 
does and does not understand in a conversation with a provider, as well as on his/her own 
personal values that might bear on the decision. S/he must also evaluate the way the provider 
represents fact and opinion, determine what the alternative options are, and try to reflect upon 
whether s/he has freedom from outside control or influence to form a preference independent of 
the provider’s. 
                                                
124 Smith, p. 185. 
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This may sound like a lot to ask of providers and patients, and it realistically may not be 
done in every interaction, particularly in situations where the event model of informed consent is 
the best that can be achieved. Informed consent regarding oxytocin augmentation in most cases, 
however, can be pursued over time, and even across multiple sessions, as the process model of 
informed consent describes. Applying a communicative ethics method of interaction would 
require a few initial encounters for providers to get practice in identifying their own biases and 
become familiar with the approach. This is much of the work of the method. Providers must still 
work to individualize the approach to each patient, but, once practiced, it is likely realistic to use 
the communicative ethics method on a regular basis, with every interaction. In fact, it is not 
dissimilar to what is taught in intensive interviewing classes at the University of Pittsburgh, 
through which medical students learn about interacting with patients through practice sessions 
with “standardized patients,” actors who take on a number of different personalities to teach 
students how to approach various interpersonal, disease-specific, or general interviewing 
challenges. It can be done, and many outpatient practitioners routinely take similar approaches to 
a variety of medical topics.125 
                                                
125 Some providers may be more comfortable with applying this approach than others: for 
instance, midwives, trained to be “with women” and focused on the support of the laboring 
patient may be more likely to embrace this approach since their training presupposes extensive 
knowledge of a patient’s preferences. In contrast, OB/GYNs may struggle more with this 
approach because their childbirth training, by and large, is about managing unforeseen 
complications of birth where they have, in practice, almost sole decision-making responsibility. 
Family physicians are likely to fall somewhere in between because they often receive their 
obstetrics training from a combination of OB/GYNs, other family physicians, and midwives. 
They may also have more time to employ this approach because they manage low-risk births 
(typically, at least) and are largely not responsible in the current practice climate for managing 
serious unforeseen complications (they hand off such cases to OB/GYN back-up physicians). 
Moreover, they come from generalist training that emphasizes the family unit, personal context, 
and treating all systems of the patient and not just one organ system. 
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Smith argues that power is accessible to patients through the implementation of ethical 
principles of respect and equal worth.126 If this is a reasonable argument or assumption, there has 
to be part of Smith’s approach that implements these principles. I would argue that her step back 
approach relies on these principles. In order to conscientiously evaluate her/his personal 
approach to medical decisionmaking as outlined in the step back approach, a provider or patient 
must have respect for the other as an independent human being, even if, in one extreme, s/he 
does not approve of, or like, that other as an individual. Equal worth has to do with the nature of 
each entity: equal worth is something individuals must believe they and others have in order to 
embody it, and, in turn, respect self and others. A belief in the equal worth of all persons is a 
significant foundation for one’s respect of those persons. Respect is directed toward non-
contingent aspects of the other, i.e., not the coincidence of the other’s preferences and values 
with one’s own, but the other’s equal worth or underlying dignity. Sarah Buss argues that the 
fundamental purpose of manners is to show respect for the dignity of others. 127 One aspect of 
informed consent, particularly as achieved through communicative speech acts such as those 
Smith describes, might be considered a professional version of displaying good manners, as Buss 
describes them. Seeking informed consent and providing information necessary to enable it has 
moral import, as doing so recognizes that “persons are ends in themselves- and must be 
acknowledged as such.”128  Similarly, reciprocal listening and critical self-reflection/evaluation 
evidence recognition of equivalent valuing of the other, even if only within the context of the 
patient-provider relationship. Showing respect allows those shown such respect access to power. 
The demand for respect and recognition of equal worth affords power to those materially, 
                                                
126 Smith, p. 204. 
127 S. Buss, “Appearing Respectful: The Moral Significance of Manners,” Ethics (July 1999) 
109, 795-826; p. 795. 
128 This is Buss’s interpretation of the moral import of treating others respectfully, p. 795. 
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socially, or “informationally” less powerful by influencing those with greater power to 
relinquish, or at least share, some of that power. Belief in equal worth encourages respect and 
encourages those with less power to seek out and accept greater power.  
With oxytocin augmentation as it currently occurs, there is typically no communicative 
action or interaction between patient and provider, particularly between patients and physicians. 
If any communication about oxytocin occurs between physicians and patients, information is 
often simply transferred. Sometimes physicians do not even witness the transfer because they 
have delegated this task to nurses, physician assistants, or even medical students with an 
order/request to “get the patient to sign the form.”  The information is transferred as content 
only, such that an explanation of what the intervention will accomplish and the risks it might 
entail are conveyed, using medical jargon, often without discussion of alternatives or values that 
might impact the decision. Saying “we’re starting a ‘pit drip’129” implies that there is no 
alternative and that the provider is recommending the intervention, and assumes that the patient 
hearing this statement knows what oxytocin is, what it is used for, what to expect after it has 
been started, and how it can affect the total course of the labor. Such cursory communication 
assumes and, in turn, implies to the patient that the patient’s preference is not equal in worth to 
the provider’s preference, and that the patient has relinquished whatever power she had over 
such decisions.  
A more open, communicative approach might be the following. After an hour and a half 
without any progression of cervical dilation in the active phase of labor, a provider might say “I 
am considering starting a drug that will increase the strength of your contractions and how often 
they occur because the progression of this birth is not what I would expect given my experience 
                                                
129 Pitocin is the pharmaceutical name for oxytocin; oxytocin is often referred to as a “pit drip,” 
slang for continuous intravenous pitocin in the clinical setting. 
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and what we know about the way labor usually progresses. The alternative is to continue 
evaluating you and the fetus without the drug, with a plan to reevaluate in 30 minutes. Do you 
have questions or concerns? How would you like me to proceed?” This approach provides the 
possibility for dialogue; indeed it requests it. The provider allows for multiple options and 
acknowledges the power of speech acts to guide the patient by providing multiple pieces of 
information regarding the indications. At the same time, the provider leaves open the space for 
questions about the indications, the way labor usually progresses and how the patient’s labor 
differs. This approach assumes that the patient has a preference of equal value as the provider’s, 
such that the provider should and does show respect for it by trying to elicit it.  
There are scenarios, however, in which communicative ethics might fail or a participant 
might undermine the intentions behind the approach. This could occur if one party is not being 
genuine and superficially elicits a conversation with all the requisite components and then uses 
the information gathered to manipulate the decision according to his/her preference. For instance, 
a provider may learn that what a patient fears most is injury to her fetus. While focusing on this 
value when interpreting options for this patient as encouraged by communicative ethics, over-
emphasizing risk, even if minimal, to the fetus at points of decisionmaking to turn the patient's 
“preference” toward the provider’s preference would undermine the goals behind the concept. 
Next I will discuss more directly the incorporation of patient preference into obstetrical decisions 
and the particular challenges with autonomy in the obstetrical patient.  
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C. AUTONOMY AND THE OBSTETRICAL PATIENT 
 
 
The Obstetrics and Gynecology Risk Research Group offers another consideration in the search 
for informed consent through shared decisionmaking, arguing that it is nearly impossible for a 
provider not to be directive while providing high quality patient care and that it is actually 
desirable for providers to be somewhat directive while getting as accurate a picture as possible of 
the patient’s values. 130 The OG Risk Research Group essentially outlines the hierarchy of 
knowledge in childbirth in an attempt to describe, and help women find, autonomy in the 
obstetrical environment. The group’s particular emphasis is on elective cesarean section, but the 
analysis and recommendations about elective cesarean section have relevance for provider-
patient discussions of oxytocin augmentation. One of the most important aspects of the patient-
provider interaction is the relationship between choice, autonomy, and a provider’s value-laden 
and directive filtering of relevant information to share with the patient facing a medical decision. 
The OG Risk Research Group addresses the intersections of choice, autonomy and directive 
filtering. They begin by discussing autonomy and choice as they are commonly understood: 
There is an obvious sense in which expanding women’s voluntary access to cesarean 
deliveries would represent an increase in the options available to women. To the extent 
that we understand patient autonomy as equivalent to informed choice, and expanding 
autonomy as a matter of expanding available choices, it may seem that any move in the 
direction of allowing women more delivery options is a move in the direction of 
enhancing women’s autonomy during birth.131 
 
They go on to state, however, that a large number of choices can sometimes reduce a patient’s 
sense of involvement in, and understanding of, the decision-making process. Even if many 
choices were available, “the physician determines the space of reasonable medical options in 
                                                
130 Obstetrics and Gynecology Risk Research Group, “Finding Autonomy in Birth,” Bioethics 
(2009) 23:1, 1-8. 
131 OG Risk Research Group, p. 2. 
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advance, and patient preferences then play a role within this frame.”132 Marmor and Krol 
delineate the prominent aspects of provider authority in decisionmaking when they write:  
Providers are at an advantage in the patient/provider relationship, the asymmetry of 
information being obvious to both parties. Providers have access to information that most 
women do not, have been trained to respond to situations in certain ways, and have been 
socialized into professional specialties that have a dominant philosophy about the labor 
process. All of that means they can significantly shape the context of choice facing 
women. Through this route, providers can influence the final decision about how pain is 
managed. So, there are some tensions between the realities of provider influence and the 
normative ideal of patient autonomy and the “helping” medical professional.133 
 
The filtering of options by providers is a communicative act that, the OG Risk Research Group 
argues, is particularly problematic in the context of childbirth. In this medical scenario, personal 
preferences of the patient typically can and should play a large role, cultural and familial 
influences carry great weight, and even the determination of appropriate and acceptable risk is an 
intimate matter. 
[T]he domain of birth and delivery decisions is one where the size of different risks will 
vary greatly depending on the meaning of the various outcomes for a particular patient, as 
these outcomes will be situated within the context of her larger narrative, needs, and 
projects, her family and community responsibilities and relationships, and her cultural 
values. In short, there is just no answer to how risky an approach to delivery is on the 
basis of statistics alone; women’s perspectives necessarily play a role in measuring risk in 
the first place. […] Substantively incorporating a patient’s values into decision-making 
about delivery is not a matter of allowing a ‘subjective’ element into an otherwise 
rationalized, evidence-based set of practices. Since any assessment of the size of a risk is 
a normative judgment that relies on a set of values, whether explicitly or implicitly, 
guidelines and practices that do not interrogate these underlying values are prone to a 
number of distortions. Careful inclusion of patients’ perspectives in determining the 
riskiness and reasonability of different medical options will likely help correct for these 
distortions and add evidence-based objectivity to the process, rather than the reverse.134  
 
                                                
132 OG Risk Research Group, p. 3. 
133 Marmor and Krol, p. S177. 
134 OG Risk Research Group, p. 4-5. 
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This perspective again helps to emphasize the importance of conscientiousness regarding what 
choices are offered, how, when, and by whom options are offered, and how they are represented 
to the patient in terms of risk and benefit profile in the context of their personal value structure.  
 The decision-making process, shared out of necessity, particularly in obstetrical settings, 
is not all about the number and nature of the choices available; rather it is about listening and 
talking to the patient about how those choices fit into her life. Conversations “ought to proceed 
via respectful probes and receptivity to emerging concerns, questions, and values, including 
receptivity to a desire not to continue the conversation at all.”135 The existing structure of regular 
and frequent prenatal visits provides an opportunity often used in just such a manner for other 
birth interventions, but rarely for oxytocin augmentation. Oxytocin augmentation can and should 
be discussed just like other birth interventions. Because provider training, pressures, and 
preferences realistically play a role in oxytocin’s use due to inconsistent guidelines for its use, 
discussions about oxytocin may have to remain somewhat different from discussions about 
interventions like epidurals. Even in today’s practice environment of groups of providers sharing 
responsibility for laboring patients, a given group of providers could decide what they consider 
medical indications for oxytocin augmentation. They could then decide how and when to pursue 
the type of informed consent process described here with their labor and delivery partners, such 
as the providers with whom they share call, residents, the nurses with whom they work, and 
students. Providers can learn about patient’s preferences about oxytocin augmentation when they 
discuss other childbirth topics, typically in the third trimester. They might also try to represent 
the major differences in provider approaches to decisions regarding oxytocin amongst the 
                                                
135 OG Risk Research Group, p. 7. 
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providers likely to deliver their patients, particularly if they work with specific colleagues about 
whom they can speak knowledgeably. 
Once patient preference is identified by applying a communicative ethics approach 
outlined above, it should be honored as long as the laboring patient and fetus remain safe. 
Preference’s role in medical decisionmaking, however, can be complex, especially in situations 
like oxytocin augmentation. There are real risks for patient safety and fetal safety, but very little 
consistency in evidence-based guidelines to balance out subjective factors playing into these 
decisions. Therefore patient preference should have that much more of a place in the decision-
making process. Preference can, of course, change at any moment during care. The weight 
appropriately accorded to either the patient’s or the provider’s preference, or even to the fetus’s 
best interests, often depends upon specific factors including the patient’s medical status and the 
range of medical interventions possible at any moment in the continuum of an illness or process 
like birth. In other words, there are often values that come to override others as medical status 
and available options change. Health of self and/or infant may well trump the patient’s 
expectations for the childbirth experience. This may ultimately result in a treatment plan that 
goes against initial patient preference. For example, if I, the patient, am tolerating labor well and 
my fetus is tolerating labor well, I don’t want oxytocin augmentation because it would increase 
the intensity and frequency of my pain and put my fetus at risk for oxygen deprivation among 
other risks. If my labor significantly slows, however, or I feel weaker and become unsure of my 
ability to endure a long labor and value any intervention that might increase my chances of a 
vaginal birth over a cesarean birth, I may be willing to entertain the notion of oxytocin 
augmentation, if my physician thinks it will help to achieve my legitimate medical goals, 
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including comfort. The provider would only know this by discussing possible outcomes of an 
evolving situation with the patient. 
 
 
 
 
D. CONCLUSION 
 
 
In light of current understandings of labor progression and ideals for patient-physician 
interactions and informed consent, the current approach to oxytocin augmentation needs to be re-
evaluated. Care to achieve informed consent for oxytocin through communicative speech acts as 
described would indicate a commitment to transparency and patient agency in the decision to 
augment with oxytocin. The key strength of thinking about patient-provider communication as 
action and interaction, rather than disclosure and mere transfer of information, is that the focus 
on interaction seeks to address existing structures of power specifically. The greater power and 
control providers have over oxytocin use is built into the system to some degree, however there 
are existing clinical practices surrounding epidurals that show change is possible and that there is 
time and space within the patient-provider interaction for more conscientious consideration of 
oxytocin augmentation and for incorporation of patient preference.  
   
 66 
 
 
 
 
 
V. BIBLIOGRAPHY 
 
 
 
 
Albers, L. L., Schiff, M., and Gorwoda, J. G. “The length of active labor in normal pregnancies.” 
Obstetrics and Gynecology (1996) 87, 355-9. 
American College of Obstetricians and Gynecologists. “Practice Bulletin #49. Dystocia and 
Augmentation of Labor.” Obstetrics and Gynecology (Dec 2003) 102: 6, 1445-1454. 
Bailit, L. J. et al. “Outcomes of Women Presenting in Active Versus Latent Phase of 
Spontaneous Labor.” Obstetrics and Gynecology (Jan 2005) 105:1, 77-79. 
Berg, J. W. et al. Informed Consent: Legal Theory and Clinical Practice. 2nd ed. (Oxford: Oxford 
University Press, 2001). 
Caton, D. et al. “The Nature and Management of Labor Pain: Executive Summary.” American 
Journal of Obstetrics and Gynecology (2002 Supplement) 186:5, S1-S15. 
Caughey, A. B. “Is There an Upper Time Limit for the Management of the Second Stage of 
Labor?” American Journal of Obstetrics and Gynecology (Oct 2009) 337-8.  
Clark, S. L. et al. “Implementation of a conservative checklist-based protocol for oxytocin 
administration: maternal and newborn outcomes.” American Journal of Obstetrics and 
Gynecology (Nov 2007)197:5, 480.e1-5. 
Clark, S. L. et al. “Oxytocin: new perspectives on an old drug.” American Journal of Obstetrics 
and Gynecology (2009) 200, 35.e1-35.e6. 
   
 67 
Clayworth, S. “The Nurse's Role During Oxytocin Administration.” The American Journal of 
Maternal/Child Nursing (March/April 2000) 25:2, 80-85. 
Emanuel, E. and L. “Four Models of the Physician-Patient Relationship.” in Ethical Issues in 
Modern Medicine : Contemporary Readings in Bioethics. 7th ed. B. Steinbock, A. J. 
London, and J. D. Arras, eds. (Boston: McGraw-Hill, 2009; 78-86). 
Faden, R. R. and Beauchamp, T. L. A History and Theory of Informed Consent. (New York: 
Oxford University Press, 1986). 
Friedman, E. A. “Primigravid labor: a graphicostatistical analysis.” Obstetrics and Gynecology 
(1955) 6, 567–89. 
Frigoletto, F. D. et al. “A Clinical Trial of Active Management of Labor.” New England Journal 
of Medicine (1995) 333:12, 745-750. 
Grotegut, C. A. et al. “Oxytocin exposure during labor among women with postpartum 
hemorrhage secondary to uterine atony.” American Journal of Obstetrics and Gynecology 
(Jan 2011) 204, 56.e1-6. 
Hamilton, B. E. et al. “Births: Preliminary Data for 2007” National Vital Statistics Reports 
(2009) 57:12, 1-23. 
Hayes, E. J. and Weinstein, L. “Improving patient safety and uniformity of care by a 
standardized regimen for the use of oxytocin.” American Journal of Obstetrics and 
Gynecology (June 2008) 198:6, 622.e1-e7. 
Hodnett, E. D. “Pain and women’s satisfaction with the experience of childbirth: A systematic 
review.” American Journal of Obstetrics and Gynecology (May 2002) 186:5, S160-S172. 
Hollander, E. et al., “Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic 
and Asberger’s Disorders.” Neuropsychopharmacology. (2003) 28, 193-198. 
   
 68 
Impey, L., Hobson, J., and O'Herlihy, C. “Graphic analysis of actively managed labor: 
Prospective computation of labor progress in 500 consecutive nulliparous women in 
spontaneous labor at term.” American Journal of Obstetrics and Gynecology (2000) 
183:2, 438-443. 
Institute for Healthcare Improvement. “About IHI.” (2011) Last accessed 21 January 2012. 
http://www.ihi.org/about/pages/default.aspx. 
 --. “Augmentation Bundle Data Collection Tool.” (2010) Last accessed 20 June 2010. 
http://www.ihi.org/about/pages/default.aspx>http://www.ihi.org/IHI/Topics/PerinatalCar
e/PerinatalCareGeneral/EmergingContent/AugmentationBundleDataCollectionTool.htm. 
Institute for Safe Medication Practices. “About ISMP.” (2012) Last accessed on 21 Jan 2012. 
http://www.ismp.org/about/default.asp. 
 --. “ISMP 2007 survey on HIGH-ALERT medications: Differences between nursing and 
pharmacy perspectives still prevalent.” (May 17, 2007) Last accessed 21 Jan 2012. 
http://www.ismp.org/newsletters/acutecare/articles/20070517.asp. 
Jonsson, M. et al. “Acidemia at birth, related to obstetric characteristics and to oxytocin use, 
during the last two hours of labor.” Acta Obstetricia et Gynecologica Scandinavica 
(2008) 87:7, 745-50. 
Kelly, G. et al. “Normal nulliparous labor: are Friedman’s definitions still relevant?” American 
Journal of Obstetrics and Gynecology (2001) 182:S129. Abstract. 
Kfuri, T. A. et al. “Medication Errors in Obstetrics.” Clinics in Perinatology (2008) Vol. 35, 
101-117. 
Kurth, L. and Haussmann, R. “Perinatal Pitocin as an Early ADHD Biomarker: 
Neurodevelopmental Risk?” Journal of Attention Disorders (2011) 15:5, 423-431. 
   
 69 
Leighton, B. L. and Halpern, S. H. “The effects of epidural analgesia on labor, maternal, and 
neonatal outcomes: A systematic review.” American Journal of Obstetrics and 
Gynecology (May 2002) 186:5, S69-S77. 
Little, M. O. et al. “Mode of Delivery: Toward Responsible Inclusion of Patient Preferences.” 
Obstetrics and Gynecology (Oct 2008) 112:4, 913-918. 
Lyerly, A. D. et al. “Risks, Values, and Decision Making Surrounding Pregnancy.” Obstetrics 
and Gynecology (April 2007) 109:4, 979-984. 
Mahlmeister, L. R. “Best practices in perinatal care: evidence-based management of oxytocin 
induction and augmentation of labor.” Journal of Perinatal and Neonatal Nursing (Oct-
Dec 2008) 22:4, 259-63. Review. 
Manson, N. C. and O’Neill, O. Rethinking Informed Consent in Bioethics. (Cambridge: 
Cambridge University Press, 2007). 
Marmor, T. R. and Krol, D. M. “Labor Pain Management in the United States: Understanding 
Patterns and the Issue of Choice.” American Journal of Obstetrics and Gynecology 
(2002) 186:5, S173-S180. 
McNiven, P. S. et al. “An early labor assessment program: a randomized, controlled trial.” Birth 
(1998) 25, 5-10. 
Miller, L. A. “Oxytocin, excessive uterine activity, and patient safety: time for a collaborative 
approach.” Journal of Perinatal and Neonatal Nursing (Jan-Mar 2009) 23:1, 52-8. 
Obstetrics and Gynecology Risk Research Group. “Finding Autonomy in Birth.” Bioethics 
(2009) 23:1, 1-8. 
   
 70 
Osterman, M. J. K., Martin, J. A., and Menacker, F. “Expanded Health Data from the New Birth 
Certificate, 2006.” National Vital Statistics Reports. Centers for Disease Control and 
Prevention (Oct 28 2009) 58:5, 1-24. 
Peisner, D. B. and Rosen, M. G. “Transition from latent to active labor.” Obstetrics and 
Gynecology (1986) 68, 448-51. 
Rogers, R. et al. “Active management of labor: does it make a difference?” American Journal of 
Obstetrics and Gynecology (1997) 177, 599–605. 
Romano, A. M. and Lothian, J. A. “Promoting, Protecting, and Supporting Normal Birth: A 
Look at the Evidence.” Journal of Obstetric, Gynecologic, and Neonatal Nursing (2008) 
37, 94-105. 
Rouse, D. J., Owen, J., and Hauth, J. C. “Active-Phase Labor Arrest: Oxytocin Augmentation for 
at Least 4 Hours.” Obstetrics and Gynecology (March 1999) 93:3, 323-328. 
Rouse, D. J. et al. “Active Phase Labor Arrest: Revisiting the 2-Hour Minimum.” Obstetrics and 
Gynecology (October 2001) 98:4, 550-554. 
Shields, S. G. et al. “Dystocia in Nulliparous Women.” American Family Physician (June 2007) 
75:11,1671-8. 
Simpson, K. R. and Knox, G. E. “Oxytocin as a high-alert medication: implications for perinatal 
patient safety.” The American Journal of Maternal/Child Nursing (Jan-Feb 2009) 34:1, p. 
8-15. 
Simpson, K. R., James, P.C., and Knox, G. E. “Nurse- physician communication during labor 
and birth: Implications for patient safety.” Journal of Obstetric, Gynecologic, and 
Neonatal Nursing (2006) 35, 547-50. 
   
 71 
Smith, J. F. “Communicative Ethics in Medicine: The Physician – Patient Relationship,” in 
Feminism & Bioethics: Beyond Reproduction. S. M. Wolf, ed. (New York: Oxford 
University Press, 1996) 184-215. 
Veatch, R. M. “Generalization of Expertise.” The Hastings Center Studies (1973) 1:2, 29-40. 
Ventura, S. J. et al. “Advance Report of New Data from the 1989 Birth Certificate.” Monthly 
Vital Statistics Report: Final Data from the National Center for Health Statistics. Centers 
for Disease Control and Prevention (15 Apr 1992) 40:12S, 1-32. 
Wei, S-Q et al. “The Effect of Early Oxytocin Augmentation in Labor: A Meta-Analysis.” 
Obstetrics and Gynecology (Sept 2009) 114: 3, 641-649. 
Williams Obstetrics. 23rd ed. F. G. Cunningham et al., eds. Last accessed 21 Jan 2012. 
http://www.accessmedicine.com/content.aspx?aID=6023669. 
Winkler, M. and Rath, W. “A risk-benefit assessment of oxytocics in obstetric practice.” Drug 
Safety (Apr 1999) 20:4, 323-45. Review. 
Young, I. M. Justice and the Politics of Difference. (Princeton: Princeton UP, 1990). 
Zhang, J. et al. “The Natural History of the Normal First Stage of Labor.” Obstetrics and 
Gynecology (April 2010) 115:4, 705-710. 
Zhang, J., Troendle, J. F., Yancey, M. K. “Reassessing the Labor Curve in Nulliparous Women.” 
American Journal of Obstetrics and Gynecology (2002) 187:4, 824-828. 
